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In eukaryotes, a number of RNA sites are modified by 2’-O methylation (2’-OMe). Such editing
is mostly guided by BoxC/D class small nucleolar RNAs (snoRNAs). These snoRNAs direct
methylation via complementary RNA-RNA interactions. 2’-OMe has so far been shown to be
present in rRNAs, tRNAs and some small RNAs and has been implicated in ribosome maturation
and translational circuitries. A substantial portion of known methylated sites in rRNA lie in close
proximity to ribosome functional sites such as regions around the peptidyl transferase center. It is
not yet clear whether many mRNAs might possess internal 2’-OMe sites. It is therefore
important to characterize 2’-OMe landscapes. We have developed a novel method for the highly
accurate and transcriptome-wide detection of 2’-OMe sites. The core principle of this method is
to randomly digest RNAs to expose 2’-OMe sites at the 3’-ends of digested RNA fragments.
Next, an oxidation step using sodium periodate destroys all fragment-3’-ends except those that
are 2’-O methylated. Only these oxidation-resistant fragments are available for linker ligation
and subsequent sequencing library preparation. We have applied our new method to the study of
ribose methylation in both Trypanosoma brucei and Mus musculus liver, and successfully
obtained rRNA 2’-OMe profiles for both organisms. Our sequencing data strongly support
experimentally validated known sites, while providing several candidates of novel sites, as well
as evidence for differential methylation. In conclusion, our method is able to reliably identify 2’OMe sites in a high-throughput manner. We are also interested in using the method to investigate
potential mRNA internal sites, the targets of “orphan” snoRNAs, which have no currently known
targets.
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Chapter I
Introduction
Since establishment of the foundations of molecular biology in the mid-1900s, additional
modes of gene regulation, which operate beyond the routes of information flow described in the
original central dogma, have been discovered. Layers of complexity to the seemingly simple
sequences of bidirectional information transfer from DNA to RNA messages, as well as
unidirectional translation from RNA molecules to proteins has been added. While Francis
Crick’s central dogma of molecular biology remains technically valid, the interconnections
between these three biomolecules have transcended generalization that the conventional
pathways of information flow. With progress made in the past few decades, we have come to
establish a more robust representation of cellular networks, which newly integrates
transcriptional and post-transcriptional regulation networks. These two aspects specifically, have
grown exponentially partially due to breakthroughs in high-throughput sequencing. Numbers of
novel non-coding RNAs such as long non-coding RNAs (lncRNAs) have been identified and
functionally characterized, while micro RNAs (miRNAs), small nuclear RNAs (snRNAs),
double strand RNA (dsRNA) etc. repertoires have been greatly expanded. More recently,
epigenetic modification and epitranscriptomic modification studies have garnered considerable
interest and momentum among the scientific field due to their significant implications in
transcriptional and post-transcription regulation respectively. Epitranscriptomics, while
significantly younger than most other fields, encompasses RNA modifications that have been
known for a very long time. The evolution of collective knowledge of each known RNA
modification, which I will discuss in greater details later in the current chapter, suggests
1

increasing scientific realization that these modifications, albeit ‘old’, might still possess
important and novel insights into biological processes and regulation.
A. Emergence of epitranscriptomics.
Epigenetics. In 1906, when William Bateson first referenced very little-known Principals of
Heredity written by Gregor Mendel, the era of modern genetics began with study of monogenic
traits, or in other words: Mendelian traits. The inheritance unit of the modern genetics is defined
by ‘gene’, which was introduced by Danish botanist Wilhelm Johannsen, where disparities
between copies of a single gene are inheritable and contributes to trait differential displayed on
different individuals within the same organism (Johannsen 1905). Later, contrary to the classic
mendelian inheritance, the patterns of inheritance for many traits were discovered to follow no
particular criteria; some traits seemingly mapped to only single genes that violate Mendelian
rules, or traits having unexplained inheritance plasticity, giving rise to the idea of non-Mendelian
inheritance. Studies have then established as complex traits, where multiple genes, sex-linked
traits or incomplete dominance/codominance come into play. (reviewed in Correns 1937, Kowles
2001, van Heyningen 2004, Cuzin 2013). With advances in biological sciences and technology,
genetics now deals with finer resolution. We are now looking at genes under single nucleotide
level and studying how change in bases affect gene expression levels, thus affecting the
phenotypes of cell types, organs and ultimately organisms. Although the early models of
inheritance still apply, they fail to account for inheritable traits or gene expression level changes
not associated with changes in actual DNA sequences. It was not until 1942, when Waddington
showed inheritable characteristics of Drosophila reacting to environmental stimuli, the study of
epigenetics (“above” genetics) was proposed (Waddington 1942). Subsequently, mechanisms
such as DNA methylation, in the form of 5-methylcytosine (m5C), was shown to regulate vital
2

cellular processes including X inactivation, and differentiation related gene expression levels
(reviewed in Felsenfeld 2007). Both DNA and chromatin methylation and demethylation since
then been implicated in the mechanism of epigenetics and incorporated into the field of study,
and epigenetics deals with a collection of modifiers that modulate gene expressions without
changing nucleotide base identity. These epigenetic modifications are categorized into several
types including DNA (mainly in the form of methylation) and histone (methylation, acetylation
and phosphorylation) modifications, each with their own sets of modifying enzymes (reviewed in
Gardner et al. 2011, Bird 2002). The growth of the epigenetics field, especially for DNA
modifications, was accelerated with the advent of the next generation sequencing technologies
(NGS), which made high-throughput identification available through combining NGS and
bisulfite treatment. Such breakthroughs allowed us to further the study of the field, which leading
to our current expansive insights into epigenetic regulatory networks that are involved in not
only basic concept of inheritance, but also in pathology and oncology of various disorders
(reviewed in Basse & Arock 2015, Mummaneni & Shord 2014, Ordog et al. 2012).
Epitranscriptomics. Similar to DNA, RNA transcripts are replete with chemical
modifications. Unlike epigenetics, which revolves around just a few types of marks, the RNA
modification repertoire is highly diverse in terms of chemical properties (reviewed in He 2010).
Up until the early 2010s, most important known RNA modifications to date were on tRNAs,
small RNAs and rRNAs, although most of these modifications have been chemically
characterized for decades, how they function was largely unclear (Motorin & Grosjean 1998).
While the most recent curation has revealed approximately 170 different types of RNA
modifications, novel modifications are still being actively discovered and added. Also, the
estimated number of sites across the transcriptome could be far more than just a few hundreds
3

(Boccaletto et al. 2018). Contrary to epigenetic marks, whose regulatory roles on gene
expressions are carried out by altering accessibility of genomic regions, RNA modifications have
been traditionally regarded as structural features that affect transcript rigidity and stability (Sloan
et al. 2017). While the collective significance of them is still being actively pursued, regulatory
functions have been ascribed for some RNA editing, including Apobec3 induced C to U
deamination, ADAR induced A-to-I editing, and N6-methyladenosine (m6A). The collective
evidence and evolution of methods to study RNA modifications have thus resulted in the
emergence of the field of transcriptomics, where chemical changes/additions to the RNA that
confer additional layers of biological functions are examined. Most of the modifications already
known for decades might not seem appealing when looked at through conventional methods, but
when coupled with recent advancements in NGS technologies, these modifications are garnering
renewed interest and optimism through the field of epitranscriptomics as a result of continuing
discoveries of their novel roles.
RNA base methylations. Modifications on RNA transcripts form a highly distinct set. The
modifications can happen in a variety of ways. For example, a methyl group can be added to an
adenosine at different positions on the nitrogenous base to form 1-methyladenosine (m1A), 2methyladenosine (m2A) etc (Dunn 1961, Starr & Fefferman 1964). A different base such as
cytosine, can also be modified with the same chemical group; In addition to structurally
distinctive modifications with the same chemical group, more than 50 different chemical
moieties are contained in the set including thiols, esters etc; all modifications but a few, which
occur on the ribose of a nucleotide (2’-O-methyl, 2’-O-ADP etc.), are found on the nitrogenous
base of the nucleotides (base methylation, reviewed in Wang & He 2014). Very interestingly,
RNA such as mRNA and tRNA can contain more than 50 different base modifications, while 17
4

occur on eukaryotic rRNA alone. Because many of them have been extensively characterized
across different species spanning all 3 domains of life, phylogenetic studies have been possible,
revealing that RNA modifications are conserved (Cantara et al. 2011, and references therein). A
table of prevalent modifications summarized from Cantara et al. (2011) and Pietro et al. (2017) is
provided here (Table 1). Although the number of modifications is large, there is a core subset of
them that have been focused on by researchers due to functional importance, prevalence of the
modification and overall distribution patterns. To have an accurate reflection of the recent status
of the field of epitranscriptomic studies, I will focus on the following RNA modifications: N6methyladenosine (m6A), 5-methylcytosine (RNA: m5C), N1-methyladenosine (m1A), Adenosine
to Inosine editing (A-to-I), pseudouridine (Ψ), and 2’-O-methylation (2’-OMe).
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Table 1. List of major RNA modifications for Archaea, Bacteria and Eukarya.
Symbol

Common Name

Found on:

m3Um

3,2′-O-dimethyluridine

mRNA

m2,2,7G

N2, N2,7-trimethylguanosine

mRNA,snRNA

m6Am

N6,2′-O-dimethyladenosine

mRNA,snRNA

m2,2G

N2, N2-dimethylguanosine

rRNA

m4 C

N4-methylcytidine

rRNA

m1acp3Y

1-methyl-3-(3-amino-3-carboxypropyl)
pseudouridine

rRNA

m3 Y

3-methylpseudouridine

rRNA

m3 U

3-methyluridine

rRNA

cm5U

5-carboxymethyluridine

rRNA

hm5C

5-hydroxymethylcytidine

rRNA

m8 A

8-methyladenosine

rRNA

Nm

2′-O-methyladenosine

rRNA,tRNA,snRNA

2′-O-methylcytidine
2′-O-methylguanosine
2′-O-methylinosine
2′-O-methylpseudouridine
2′-O-methyluridine
m6,6Am

N6, N6,2′-O-trimethyladenosine

rRNA,mRNA

m2 G

N2-methylguanosine

rRNA,snRNA

m1 A

1-methyladenosine

rRNA,tRNA

m1 G

1-methylguanosine

rRNA,tRNA

m1 Y

1-methylpseudouridine

rRNA,tRNA

m2 A

2-methyladenosine

rRNA,tRNA

acp3U

3-(3-amino-3-carboxypropyl) uridine

rRNA,tRNA

m3 C

3-methylcytidine

rRNA,tRNA

m5Um

5,2′-O-dimethyluridine

rRNA,tRNA

m4,4Cm

N4, N4,2′-O-trimethylcytidine

rRNA,tRNA
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ac4Cm

N4-acetyl-2′-O-methylcytidine

rRNA,tRNA

ac4C

N4-acetylcytidine

rRNA,tRNA

m7 G

7-methylguanosine

rRNA,tRNA,mRNA

m6 A

N6-methyladenosine

rRNA,tRNA,mRNA,snRNA

pseudouridine

rRNA,tRNA,mRNA,snRNA

D

Dihydrouridine

rRNA,tRNA,snRNA

m1Nm

1,2′-O-dimethyladenosine

tRNA

1,2′-O-dimethylguanosine
1,2′-O-dimethylinosine
m1 I

1-methylinosine

tRNA

msms2i6A

2- methylthiomethylenethio-N6-isopentenyladenosine

tRNA

k2 C

2-lysidine

tRNA

ms2io6A

2-methylthio-N6-(cis-hydroxyisopentenyl)
adenosine

tRNA

ms2hn6A

2-methylthio-N6hydroxynorvalylcarbamoyladenosine

tRNA

ms2m6A

2-methylthio-N6-methyladenosine

tRNA

ms2t6A

2-methylthio-N6-threonylcarbamoyladenosine

tRNA

s2Um

2-thio-2′-O-methyluridine

tRNA

s2 C

2-thiocytidine

tRNA

s2 U

2-thiouridine

tRNA

Ar(p)

2′-O-ribosyladenosine (phosphate)

tRNA

Gr(p)

2′-O-ribosylguanosine (phosphate)

tRNA

imG-14

4-demethylwyosine

tRNA

s4 U

4-thiouridine

tRNA

m5Cm

5,2′-O-dimethylcytidine

tRNA

mchm5Um

5-(carboxyhydroxymethyl) -2′-Omethyluridine methyl ester

tRNA

inm5s2U

5-(isopentenylaminomethyl) -2-thiouridine

tRNA
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inm5Um

5-(isopentenylaminomethyl)-2′-Omethyluridine

tRNA

inm5U

5-(isopentenylaminomethyl)uridine

tRNA

nm5se2U

5-aminomethyl-2-selenouridine

tRNA

nm5s2U

5-aminomethyl-2-thiouridine

tRNA

ncm5Um

5-carbamoylmethyl-2′-O-methyluridine

tRNA

ncm5U

5-carbamoylmethyluridine

tRNA

cmnm5s2U

5-carboxymethylaminomethyl-2-thiouridine

tRNA

cmnm5Um

5-carboxymethylaminomethyl-2′-Omethyluridine

tRNA

cmnm5U

5-carboxymethylaminomethyluridine

tRNA

f5Cm

5-formyl-2′-O-methylcytidine

tRNA

f5C

5-formylcytidine

tRNA

ho5U

5-hydroxyuridine

tRNA

mcm5s2U

5-methoxycarbonylmethyl-2-thiouridine

tRNA

mcm5Um

5-methoxycarbonylmethyl-2′-O-methyluridine

tRNA

mcm5U

5-methoxycarbonylmethyluridine

tRNA

mo5U

5-methoxyuridine

tRNA

m 5 s2 U

5-methyl-2-thiouridine

tRNA

mnm5se2U

5-methylaminomethyl-2-selenouridine

tRNA

mnm5s2U

5-methylaminomethyl-2-thiouridine

tRNA

mnm5U

5-methylaminomethyluridine

tRNA

tm5s2U

5-taurinomethyl-2-thiouridine

tRNA

tm5U

5-taurinomethyluridine

tRNA

m2Gm

N2,2′-O-dimethylguanosine

tRNA

m2,7Gm

N2,7,2′-O-trimethylguanosine

tRNA

m2,2Gm

N2, N2,2′-O-trimethylguanosine

tRNA

io6A

N6-(cis-hydroxyisopentenyl) adenosine

tRNA

ac6A

N6-acetyladenosine

tRNA

g6 A

N6-glycinylcarbamoyladenosine

tRNA
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hn6A

N6-hydroxynorvalylcarbamoyladenosine

tRNA

i6 A

N6-isopentenyladenosine

tRNA

m6 t6 A

N6-methyl-N6-threonylcarbamoyladenosine

tRNA

t6 A

N6-threonylcarbamoyladenosine

tRNA

OHyW

hydroxywybutosine

tRNA

OHyWy

methylated undermodified hydroxywybutosine

tRNA

mimG

methylwyosine

tRNA

o2yW

peroxywybutosine

tRNA

cmo5U

uridine 5-oxyacetic acid

tRNA

mcmo5U

uridine 5-oxyacetic acid methyl ester

tRNA

imG

wyosine

tRNA

Q

queuosine

tRNA

oQ

epoxyqueuosine

tRNA

galQ

galactosyl-queuosine

tRNA

manQ

mannosyl-queuosine

tRNA

preQ0

7-cyano-7-deazaguanosine

tRNA

preQ1

7-aminomethyl-7-deazaguanosine

tRNA

I

inosine

tRNA, mRNA

m5 C

5-methylcytidine

tRNA, mRNA

m2,7G

N2,7-dimethylguanosine

tRNA, mRNA
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M6A is the most abundant base methylation epitranscriptomic mark known to date. This
modification was originally discovered in tRNAs rRNAs and poly-A RNA fractions (Bokar et al.
1997). M6A was originally thought to modulate tRNA and rRNA folding structures and
stabilities due to its base pairing weakening properties. Although in vitro biochemical techniques
in earlier studies that used synthetic oligos, as well as C14 methionine labeling techniques, gave
insights of the potential functions of the modifications, the physiological relevance of these in
vitro results was not established (reviewed in Saletore et al. 2012). At the same time, mapping
sites had proven to be difficult and laborious using low-throughput HPLC or thin-layer
chromatography; most frustratingly, it was hard to determine where to look in longer transcripts
such as rRNAs and mRNAs (reviewed in Zhao et al. 2016). Thus, progress on the 5-decade-old
modification remained stagnant. However, emergence of NGS technology brought capability of
high-throughput DNA sequencing, which was then developed to also support RNA sequencing.
It did not take long before the next gen RNA sequencing technology was adapted for highthroughput m6A detection. Dominissini et al. (2012) and Meyer et al. (2012) took advantage of
the existence of m6A antibodies to immunoprecipitate RNAs with the modification followed by
subjecting the RNA fragments to RNA sequencing procedures after fragmentation. Subsequent
alignment of the sequenced fragments would then allow assigning intervals where RNAs are
modified down to 25-100 base pair resolution transcriptome-wide. Due to the nature of the
immunoprecipitation, it was not possible to obtain single-base resolution. However, this
experimental design allowed researchers to finally generate m6A profiles, to perform association
studies, and to eventually narrow in on genes/pathways of interest followed by validation using
traditional methods. Since then a number of biological pathways involving the modification have
characterized, for example the findings that: naturally occurring modifications with m6A affect

10

levels of pluripotency-promoting transcripts through transcriptional regulation. Thus disrupting
steady-state demethylation alters embryonic stem cell (ESC) transition from the naïve to the
primed state, while hyper demethylation contributes to tumorigenesis (Cui et al. 2017); m6A ,
highly enriched in the brain, can also regulate splicing, and is involved in brain development, sex
determination in Drosophila via alternative splicing, as well as human x chromosome
inactivation(Lence et al. 2016, Patil et al. 2016, Xiao et al. 2016); and the modification has also
been recently shown to directly impact mRNA translation elongation through altered base
pairing thermal dynamics with tRNAs (Choi et al. 2016). Owing to the now expanded lists of
m6A writers (methyltransferases), erasers (demethylases), readers (m6A binding proteins) and
clear biological functions characterized (RNA stability, signaling and splicing), m6A is the
epitome of the field of epitranscriptomics with constructions of m6A landscapes playing vital
roles in discoveries/validations of specific concepts and results (Figure 1, reviewed in Niu et al.
2012, Zhao et al. 2016).

11

Figure 1. Functional Roles of m6A
A simple diagram summarizing m6A mediated functions. Black arrows represent functions mediated
under nominal conditions. The green arrow represents methylation/demethylation imbalance, resulting in
decrease in overall methylation level.

12

Diverse functions of RNA modification by means of N6-methyladensine

13

Both m5C and m1A are less well characterized epitranscriptomic marks compared to m6A.
Similar to m6A, m5C and m1A are RNA modifications described many years ago (Yuki &
Fujiwara 1976, Hong et al. 1997). Like its sibling DNA m5C, RNA m5C had been shown to be
potentially present on polyadenylated RNA decades ago, when it was discovered; although
possessing almost the same chemical properties as m5C in DNA, the biological functions of
RNA m5C’s remain largely elusive (reviewed in Oerum et al. 2017). Unlike m6A, which has
been extensively mapped across different RNAs, cell types and species, m5C has only a few
available transcriptome wide mapping results available for further study to date. Bisulfite
sequencing, which is the high-throughput detection method available for both DNA and RNA,
has been available and became a rather mature detection method (Schaefer et al. 2009). Thus, the
pace of m5C profiling has been picking up recently, and studies have started filling in some gaps
including: 1) analysis of m5C conservation in plant rRNAs (Burgess et al. 2015); 2) differential
methylation studies between mouse organs (Johnson et al. 2016); 3) evidence of m5C shaping
chromatin organization, affecting drug resistance to leukemia(Cheng et al. 2018); and 4)
correlation of 5hmC, a derivative of m5C, with global modification patterns and glioblastoma
survival (Amort et al. 2017 and references therein). M1A on the other hand, was identified as a
novel modification on poly(A)+ RNAs. It was only detected in mRNAs and some long noncoding RNAs in 2016 after antibody-based IP coupled with NGS was adapted from m6A
detection method (Dominissini et al. 2016). Realization of the importance of high-throughput
detection techniques has led to the active development of more methods for its detection and
mapping (Ritchey et al. 2017). Although, available datasets for both m5C and m1A mainly point
to structural roles contributing to RNA stability, further probing and validations are required to
examine whether these two modifications could have similar levels of functions to m6A. We

14

expect to gain more insights as more data are generated from current methods and methods being
actively developed.
Guide RNA dependent modifications. m6A, RNA m5C and m1A are added to target RNA
bases through guidance to specific RNA motifs by other protein components that directly
recognize the motifs. On the other hand, A-to-I editing and pseudouridylation are guide RNA
dependent. A-to-I RNA editing is the chemical reaction where adenosine undergone hydrolytic
deamination by adenosine deaminases that act on RNA (ADAR) protein family members,
resulting in inosine, which base-pairs with C instead of U and functions genetically and
biochemically in the cell as guanosine (Polson et al. 1991). This is one of the special cases where
modification changes the nucleotide identity; however, as the field of epitranscriptomics evolves,
the definition has been expanded to include modifications confer regulatory functions. And the
current consensus is that the A-to-I editing can be considered as a type of epitranscriptomic
change (reviewed in O’Connell 2015). A-to-I editing, which has both nuclear and cytoplasmic
components, occurs on dsRNAs including sense-anti-sense paired transcripts and
intramolecularly paired repeat elements such as Alu, SINE and LINE elements; editing sites of
ADARs were originally discovered through sequence mismatches when comparing genomic
sequences with cDNA sequences from particular RNA transcripts. ADAR editing has been
reported to regulate miRNA processing and efficacy in cytoplasm; it has also been shown that
elicitation of interferon responses against dsRNAs are suppressed by ADAR editing (reviewed in
Nishikura 2010). It was not until NGS became available that A-to-I editing sites could be
analyzed on a large scale (reviewed in Nishikura 2016). From past accumulated evidence
together with recent deep sequencing studies, we now have a more comprehensive understanding
of the actions of ADAR family proteins. It has been demonstrated from the collective profiles of
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the editing sites that ADAR proteins exhibit two modes of activity – promiscuous editing and
site selective editing. As a result of promiscuous editing, a significant portion of the human
transcriptome has extensive stretches of A to I conversions, with Alu RNAs being the majority. It
was shown to have vital role in preventing cellular damage from dsRNA mediated innate
responses. Such function is highly correlated with inhibition of nuclear export of the highly
edited RNA transcripts into the cytoplasm (reviewed in Nishikura 2010, O’Connell et al. 2015).
Site-selective mode, on the other hand, pinpoint and modify a small group of adenosines resulted
from limited imperfect base-pairing of neighboring bases. Such editing mode has been reported
to occur on several mRNA transcripts, including AMPA receptor subunit GluR-B, K(V)
potassium channel etc. The editing on the GluR-B, a glutamate gated ion channel, was shown to
be important for brain functions (Higuchi et al. 1993, Greger et al. 2002, Greger et al. 2003). It
was also reported that editing on K(V) mRNA is a mechanism of controlling channel inactivation
(Bhalla et al. 2004).
ADAR editing is also abundantly enriched during viral infections, such as by Murine
polyomavirus (MPyV). During infection, overlapping portions of viral RNA concatemers are
promiscuously edited (Chen & Carmichael 2009, Garren et al. 2015). Consistent with an in vitro
study, where viral gene expressions were downregulated by editing, the RNA modification can
have additional role in anti-viral responses (Gu et al.2009). Although such observations indicate
certain roles the modification play during said biological processes, whether they are the cause or
result are still being debated and will need to be verified. It is encouraging to see that creatives
tool have been actively developed for the study of ADAR editing: CRISPR guide RNAs are
introduced to form double stranded structures with targets, while ADAR is tethered to the dCas9
for targeted editing (Fukuda et al. 2017). Such strategy would allow generation of related tissue
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cultures and transgenic mice lines for easier study of the editing under more physiological
relevant conditions. While we wait for more studies to come out, clinical applications of the
ADARs are also being explored.
Recent methodological advancements have also enabled thorough profiling of RNA
pseudouridylation, which was the first RNA modification discovered and which results in the
conversion of uridine to pseudouridine through RNA guided isomerization of the uridine by
pseudouridine synthase (PUS) (Massenet et al. 1999). Following early discoveries made on
tRNAs and rRNAs, the high density of this modification was generally believed to be the most
abundant cellular RNA modification (Cohn and Volkin 1951). The RNA guiding the
modification is a class of small nucleolar RNA (snoRNA) that possesses RNA motifs called box
H/ACA motifs. snoRNAs are assembled into ribonucleoprotein particles (snoRNPs) that possess
both targeting and enzymatic functions. The H and ACA motifs together with neighboring
sequences determine target RNA sites, while scaffolding proteins and PUS are assembled around
the boxes (reviewed in Li et al. 2016). Pseudouridylation patterns have been shown to be highly
conserved in rRNAs, tRNAs and small nuclear RNAs (snRNAs). Pseudouridines have been
considered to mainly contribute to rRNA folding and occur in a conserved pattern around the
peptidyl transferase center (ptc) -interacting region (reviewed in Ge & Yu 2013). Pseudouridine,
together with 2’-O methylation both utilize the snoRNA machinery. Although two modifications
are chemically different, they conventionally seem to have similar functions. Importantly, a
transcriptome-wide deep sequencing detection method (Pseudo-seq) using a chemical modifier
specific to pseudouridine was recently developed to identify pseudouridines at single-base
resolution (Schwartz et al. 2014, Carlile et al. 2014). Since then, additional novel
pseudouridylation sites in both non-coding RNAs and mRNAs have been identified, at the same
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time, this could be where pseudouridylation and 2’-O methylation diverge. Besides expanding
the pseudouridylation landscape, pseudouridine profiles generated so far has shown some
potential correlations between the modification and diseases. For example, normal and
dyskeratosis congenita patient pseudouridylation patterns were profiled and results suggested
strong enrichment and differential modification on telomerase RNA component (TERC), which
is implicated in the pathology (reviewed in Zhao & He 2015). Li et al. (2016) have noted a
renewed interest and speculated the potential role of pseudouridine in gene regulation.
Although there are currently a number of other examples of RNA modification, such as C-toU editing by APOBEC family protein members (which have also been identified as DNA
modifiers), I feel the critical point to emphasize is the importance of development of new
methodologies that allow the of biological processes/components and discoveries of new
applications has been properly expressed. In the rest of this thesis, I will focus on a single RNA
modification, 2’-O-methylation.
B. Ribose methylation/2’-O-methylation.
Mechanisms of snoRNA guided 2’-O-methylation. 2’-O-methylation is the addition of a
methyl group to the 2’-O-position of a nucleotide sugar backbone-ribose-, which is why it is also
referred to as ribose methylation (Figure 2A). Deposition of the modification is an RNA-guided
event similar to that of the RNA pseudouridylation, where snoRNAs play a central role in the
process. Contrary to pseudouridylation, ribose methylation is guided by snoRNAs that contain
box C/Ds instead of box H/ACAs, despite the existence of rare snoRNAs that can guide both 2’O-methylation and pseudouridylation.

18

Figure 2. Box C/D snoRNA guided 2’-O-methylation and Box C/D snoRNP biogenesis
(A) A simplified diagram for box C/D snoRNA guided 2’-O-methylation. The addition of one methyl
group, which is highlighted in red on the bottom panel, to the ribose 2’-O position is carried out by box
C/D snoRNPs.
(B) Box C/D snoRNP biogenesis for human is summarized here. snoRNA biogenesis for other eukaryotes
and Archaea undergo same procedures, while Nop56, Nop58, 15.5k and fibrillarin are replaced with other
protein homologs. Box H/ACA snoRNPs biogenesis also share the same mechanism with box C/D
snoRNPs with the exception of recruiting different scaffolding and catalytic proteins.
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Box C/D snoRNAs (H/ACA biogenesis is similar) are processed inside the nucleus from
intronic regions of RNA PolII transcribed host RNAs that undergo splicing. Between steps of
spliceosome assembly to lariat formation during co-transcriptional splicing of the host RNAs,
scaffolding proteins 15.5K, Nop58, Nop56 and the methyltransferase Fibillarin become
associated with the C/D boxes (reviewed in Kiss 2006). When the lariat is debranched,
exonuclease degradation occurs to eliminate the entire intron except for the snoRNA portion
protected by the bound proteins, forming functional snoRNPs (Figure 2B, Baserga et al. 1991,
Hirose et al. 2003). Some snoRNPs permanently localize to Cajal bodies and are subsequently
named small Cajal body-specific RNPs (scaRNPs). These RNPs carry out modifications of small
nuclear RNAs (snRNAs). Some others transiently localize to Cajal bodies before eventual
trafficking into the nucleolus, while the rest localize directly to the nucleolus (Kiss et al. 2006).
These RNPs directly participate in the maturation of ribosomal RNAs by means of extensive
methylation prior to the assembly of ribosomal subunits and processed rRNAs inside the
nucleolus (Figure 3, reviewed in Pelletier et al. 2017). It has been known that tRNAs are also
internally methylated, while miRNAs are 2’-O-methylated at their 3’ ends. These RNAs are
methylated through site-specific protein-mediated processes (reviewed in Clouet-D’Orval et al.
2005). Interestingly, while there is no evidence indicating eukaryotic tRNA and miRNA
methylation through snoRNPs, both protein-mediated and guide RNA-dependent mechanisms
occur on Archaea tRNAs (Renalier et al. 2005).
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Figure 3. Box C/D snoRNP trafficking and its roles in RNA processing
Box C/D snoRNPs either directly localize to nucleolus, or transiently travel to cajal bodies before
localization to nucleolus. Box C/D snoRNPs carry out 2’-O-methylation on pre-rRNAs, which is a
necessary step for rRNA maturation and ribosome biogenesis. The snoRNPs also 2;-O-methylate snRNAs
inside Cajal bodies.
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Box C/D snoRNAs fold into stem loop structures but retain spacers of at least 12-bp on each
side of the stem loop (between Box C and Box D’, and between Box C’ and Box D), and these
anneal to target substrates; the spacer sequences form a maximum of 10-bp complementary base
pairs with targets in Archaea, while lengths of duplexes are rather variable in eukaryotes (Kiss
2001, Yang et al. 2016). In most cases, methylation, catalyzed by fibrillarin, occurs at the 4th or
5th base in the base pairing region upstream of box D and/or D’, and mismatches around the
region abolish methylation activity (Figure 4, Cavaillé, & Bachellerie 1998). 2’-OMes densely
populate rRNAs and possibly other RNAs, necessitating a number of different snoRNAs guiding
the extensive modifications. Interestingly, cases where one snoRNA can mediate the methylation
of multiple sites in human, such as U24 snoRNA on 28S rRNA base location 2350 and 2364,
have been observed possibly due the repetitive nature of some regions of rRNAs. Not
surprisingly, box H/ACA snoRNAs can also display such a property including ACA17 snoRNA,
which guides pseudouridylation on 28S rRNA at both base position 4678 and 4956. In some rare
cases, different snoRNAs can target the same site. Taking U51 and U32A for example, each can
target base position 1523 on 28S rRNA, but at the same time, each has a different target at a
different position (https://www-snorna.biotoul.fr/browse.php?sno=CDBox). Whether this
redundancy is selected for during evolution or just a coincidental remains unclear. It is possible
that 2’-OMe on 28S rRNA position 1523 contributes more either structurally or functionally,
studies mutating the site or probing structural properties might provide some answers.
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Figure 4. Typical box C/D snoRNA guide and target
Box C/D snoRNA sequences immediately upstream of box D or box D’ base pair with target RNA to
form duplex structures. In most cases, either the 4th or the 5th base upstream of the two boxes is
methylated.
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Additional observed snoRNA properties. The snoRNA structures in general follow the rule
shown in Figure 4, but there are a few exceptions. U85 scaRNA was the first scaRNA discovered
as a box C/D and box H/ACA hybrid. This composite scaRNA seems to be functional as
overexpression of a snRNA chimera has shown correct 2’-O-methylation and pseudouridylation
(Jády and Kiss 2001). Since then, 3 more composite scaRNAs, as well as dual boxC/D and dual
box H/ACA snoRNAs have been identified. These special snoRNAs (scaRNAs) were manually
curated due to highly altered secondary structures and folding dynamics. Although the number of
these snoRNAs are quite low (13), they are fairly conserved across species dating back to early
vertebrates (Lestrade 2006, Marz et al. 2011). Therefore, further investigation might provide
insights on the importance of conservation in these RNAs.
Although the number of curated known and predicted box C/D snoRNAs in human alone
amounts to more than 250 in human and close to 350 in mouse, a significant portion of them
have no known methylation targets; conversely, yeast possesses much less snoRNAs and
majority of them are well known, most likely due to its inherently small genome (Table 2).
Compared to rRNAs, which are abundantly expressed and where matching 2’-O-methylation
guide snoRNAs have been identified, finding the targets of the snoRNAs with no obvious
complementarity to rRNAs has proven to be difficult (Jády & Kiss 2000). The major hurdle
presented to the community has been that each base pairing sequence between a snoRNA guide
and its target is so short. Validating predicted pairs is not feasible without already having a list of
high confidence modification sites for cross checking, as predictions based on base pairing alone
can generate hundreds or even thousands of potential methylation sites. Thus, these snoRNAs
without known targets are designated “orphan” snoRNAs (Jorjani et al 2016).
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Table 2. Summary of snoRNAs from curated database.

Species
Human
Mouse
Yeast

Total # of known
and predicted C/D
snoRNAs
213
327
47

# with rRNA
targets
129
132
45

# with snRNA
targets
5
5
-

# with unknown
targets
79
193
2

snoRNA list summarized from snoRNA Orthological Gene Database (snoopy):
http://snoopy.med.miyazaki-u.ac.jp/snorna_db.cgi (Yoshihama & Kenmochi 2013)
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Interestingly, a number of snoRNAs of both box C/D and box H/ACA types, and both orphan
and non-orphan have also been found to be processed into miRNA like structures and possess
miRNA activities. Some of these snoRNA derived miRNAs such as SNORD78-miRNAs have
been reported to be correlated with non-small- cell lung cancer, indicating potential functions
outside of the conventional scope (Saraiya & Wang 2008, Ender et al. 2008, Scott et al. 2009,
Brameier et al.2011). Although it is possible that the effects mentioned are purely contributed
from miRNA forms of these snoRNAs, it has not been explored whether potential 2’-Omethylations are carried out by these snoRNAs, whether the methylation levels also correlate
with pathology of said cancers. In addition, snoRNAs are found to be part of two types of
unusual RNAs: sno-lncRNAs and SPA-ncRNAs (Wu et al. 2016, Yin et al. 2012). Functions
claimed in these studies attempt to explain Prader Willi syndrome in a way that complements our
hypothesis that 2’-O-methylation plays an important or even central role, and they will be briefly
discussed in a later section.
Mechanism of RNA guide-independent 2’-O-methylation. As mentioned above, ribose
methylation in eukaryotes mainly employs a snoRNA independent mechanism for tRNAs and
miRNAs. For tRNAs, most of the well characterized methyltransferases, termed Trm(s), were
discovered in bacteria and yeast. Trms belong to a class of S-adenosyl-L-methionine (AdoMet)dependent enzymes in the SPOUT superfamily (Tkaczuk et al. 2007 and references therein).
Currently, Trm7 has been identified to directly deposit methyl group at 2’-O positions on bases
of tRNA-Phe, tRNA-Trp, and tRNA-Leu in yeast. FTSJ1 has since then been reported to be
human homolog to the Trm7 (Pintard et al. 2002, Guy et al. 2017, Somme et al. 2014, Bourgeois
et al. 2017 and references therein). Hen1, a helix-loop-helix (HLH) family transcription factor
harboring both a dsRNA binding domain, as well as a 2’-O-methyltransferase domain, is another
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2’-O-methyltransferase ubiquitously expressed (Begley et al. 1992, Yu et al. 2005). Owing to
flexibility in its RNA binding domain, Hen1 is able to bind to and catalyze 2’-O-methylation of
the 3’- ends of piRNAs and miRNAs, whose precursors exist in partially double stranded forms.
Similar to Trm7, Hen1 is highly conserved and homologs are found across species within
eukaryotes (Brown et al. 1992, Kirino& Mourelatos 2007, Saito et al. 2007).
In yeast and mammals, 2’-O-methylation of mRNA cap structures is also carried out through
non-guide-RNA pathway. mRNA 5’-capping is an important process for mRNA biogenesis.
Successful capping protects RNA transcripts from 5’to 3’ exonuclease degradation, enables
nuclear export and is required for most translation initiation events in the cytoplasm. A typical
5’-cap structure consists of cap0, cap1 and cap2 components, where the inverted 7methylaguanisime (cap0) is linked to two cap1-cap2, which are the first and second transcribed
bases, through triphosphate linkage. (reviewed in Smietanski et al. 2014 & Hocine et al. 2010).
FTSJD1 and FTSJD2, were identified to be the methyltransferases for mRNA cap1 and cap2
through methyltransferase domain homology to tRNA and rRNA 2’-O-methyltransferases (Trm7
and fibrillarin). As part of the final cap structure, virtually all mRNAs are methylated at cap0 and
cap1, while only a subset of the mRNAs contains cap2 2’-O-methylation (Furuichi et al. 1975,
Werner et al. 2011).
Functions of ribose 2’-O-methylation. The translation machinery is one of the most vital
components of biological units across all domains of life. In mammals, mRNA translation is
carried out by ribosomes in the cytoplasm with the help of tRNAs in decoding mRNAs. The
ribosomal complex is responsible for synthesis of all cellular proteins. Even ‘lifeless’ viruses rely
host ribosomal machinery for propagation. Due to the important nature of the translation, the
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upstream and downstream processes are heavily regulated as evidenced by plethora of
transcriptional and post transcriptional regulation pathways. (reviewed in Walsh & Mohr 2011).
As one of best characterized RNA species, human rRNA contains at least 150 2’-Omethylated bases. Although known methylation patterns on rRNA are generally conserved from
yeast to human, mostly occurring in regions close to the peptidyl transferase center (PTC),
functions of these epitranscriptomic marks remain inconclusive (Decatur & Fournier 2002).
Several studies attempting to elucidate exact functions of the modification have resulted in
underwhelming results. Serial or aggregated deletions and or mutations of tens of box C/D
snoRNA guides that targets methylation sites near core region of rRNA yielded mild phenotypes
and growth defects (Esguerra et al. 2008 and references therein). Experiments where multiple
modification sites were unmethylated seemed to have produced slightly stronger phenotypes
albeit mild nonetheless; similarly, snRNAs, which also possess extensive and conserved 2’-Omethylation patterns, have been shown to have mild defects when snoRNAs targeting them are
manipulated (Karijolich & Yu 2007 and references therein). Taken together, these data suggest
that 2’-O-methylation on rRNAs and snRNAs might function as structural enhancement features
that contribute to RNA transcript rigidity without individually being essential (reviewed in Sloan
et al. 2017,). Surprisingly, homozygous knock out of fibrillarin, the 2-O methyltransferase
component of the box C/D snoRNPs, proved to be lethal in yeast and resulted in development
lethality in mouse embryos; meanwhile, heterozygous KO of the gene had no noticeable
phenotype, suggesting a strong tolerance for protein level fluctuations; interestingly the same
study showed that correct localizations of the snoRNAs are also disrupted under homozygous
KO conditions, consistent with the requirement of the methyltransferase binding for snoRNA
maturation (Newton et al. 2003). Although not reported in the publication, there has been no
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available fibrillarin KO cell line or conditional fibrillarin KO mouse, which might signify that
depletion of fibrillarin is also lethal even later in developmental stages. Such effects, contrary to
the putative function of the methylation, suggest that there are two potential models. First,
snoRNAs are structurally essential. Depleting fibrillarin depletes snoRNAs and the cumulative
effect of elimination of all 2’-O methylation is lethal. Second, at least some specific ribose
modification(s) is/are functionally essential, requiring catalytic activity of fibrillarin, and there
are site(s) not known associated with lethal effect resulted from fibrillarin knockout (Figure 5).
For 2’-O-methylation, although it is highly likely that it contributes to RNA structural stability,
as well as influences folding as evidenced by its distribution patterns in different RNA species
and studies performed on rRNA biochemical properties (Dennis et al. 2015, Satoh et al. 2000),
we cannot disregard the possibility that the modification has additional functions and is more
broadly distributed over the transcriptome at the same time.
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Figure 5. Models for potential roles of 2’-O-methylation.
See text for details.
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RNA-independent ribose methylation biochemically achieves the same goal as snoRNA
guide methylation in eukaryotes and Archaea, however, their substrates are largely different. The
strong conservation of various 2’-O-methylation mechanisms suggests that having the
modification is likely conferring some type(s) of evolutionary advantage. It has been known that
there exist everlasting power struggles between organisms, such as higher eukaryotes against
viruses, throughout the evolutionary process. As viruses evolve, other organisms have to keep up
the pace to fend off potential viral infection. Such back and forth competition has shaped our
immune mechanisms and viral infection strategies. 2’-OMes at mRNA 5’-cap in higher
eukaryotes and some viral transcripts seem to be one hallmark of such a process. Hosts utilize 2’OMe on the 5’-cap to distinguish self from non-self since mRNA from viruses that replicate in
the cytoplasm are modified differently. The lack of 2’-OMe at cap structures can elicit interferon
induced responses, thus attenuating viral replication. Interestingly, some viruses encode their
own 2’-O-methyltransferases, evading such host immunity (Daffis et al. 2010, Hyde & Diamond
2015, Züst et al. 2011). Further, non-cap internal 2’-OMe was found in falvivirus NS5
transcripts. The presence of this modification reduced the rate of translation and RNA synthesis,
which might indicate an alternative strategy to elude host immune system detection (Dong et al.
2012). A similar strategy has also been found to be exploited by bacteria, where a single specific
ribose methylation on a bacterial tRNA is enough to antagonize TLR7/8 induced innate
immunity (Rimbach et al. 2015, Schmitt et al. 2017). In another unusual case associated with
immunity, a naturally occurring 2’-OMe on human 18S rRNA has been reported to be capable of
stimulating, not suppressing, the TLR7/8 response pathway (Jung et al. 2015). Although, it is
unclear whether this methylation event is linked to any potential function, it might be worth
studying under the scope of autoimmunity.
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Although current lines of evidence suggest 2’-OMe could be multi-functional, a
comprehensive description of the consequences of modification is lacking. Taking all available
findings into consideration, it is clear that we need more data points to make proper
generalizations. Here are some of the questions we can ask. How strongly do internal 2’-OMes
of some viruses affect viral life cycles and how widespread, is this mechanism? Is TLR7/8
activating 2’-OMe only a rare case? Do 2’-OMe functions vary, and by how much, between cell
types? How variable is 2’-O-methylation on rRNA, and does 2’-O-methylation variability
correlated with cellular phenotypes? Can RNA-guided methylation occur in the cytoplasm or
nucleoplasm, instead of only in the nucleolus and Cajal bodies?
C. Insights into 2’-OMe in humans.
Despite the observation that snoRNA derived miRNA-like RNAs are found in the cytoplasm,
full-length snoRNAs have never been shown to localize the same way. A notable analogy
supporting guide RNA-dependent 2’-O-methylation on mRNA is ADAR family protein
localization. From imaging experiments, snoRNPs seem to almost exclusively localize to the
nucleolus and Cajal bodies, consistent with their putative functions. Nuclear ADAR1 and
ADAR2 also show exclusive nucleolar localization; however, their dsRNA substrates are
nucleoplasmic. Indeed recently, a group of ribosomal protein L13a (Rpl13a) intron encoded
snoRNAs were discovered in the cytoplasm. While U32a, U33, U34 and U35a transcribed from
the locus mainly reside inside typical locations in the nucleolus, stress conditions, specifically
reactive oxygen species, triggered significant relocation into cytoplasm in a NADPH oxidase
(Nox) regulated manner (Michel et al. 2011). These snoRNAs are guides for known rRNA 2’-Omethylation sites, further expanding the multi-functionality of box C/D snoRNAs. This study
showed that the snoRNAs are in the form of intact snoRNPs instead of potentially processed sno36

miRNAs, suggesting any function implicated by the Nox regulated snoRNA relocation is
independent of known mechanisms (Holley et al. 2015). Furthermore, the study also detected
most of the known snoRNAs in the cytoplasm after ROS triggered stress, therefor identifying a
broader spectrum of the phenomenon than with Nox alone.
Confirmation of cytoplasmic snoRNAs opened the further possibility that snoRNPs could
indeed modify mRNA internal sites, thus providing one potential explanation to major missing
links between snoRNAs and human cancers, which have also been studied extensively recently.
Currently, clinical studies have created correlations such as loss of: SNORD50 in prostate
cancer, SNORD42 in non-small cell lung cancer, SNORD47/76 in glioblastoma, SNORD47/113
hepatocellular carcinoma and SNORD44 head and neck squamous cell carcinoma and breast
cancer, while SNORD50 is deleted in around 10% cases of most human cancers; even a fraction
of box C/D snoRNAs are now characterized as biomarkers in leukemia (Patterson et al. 2017 and
references therein, Ronchetti et al. 2013, Siprashvili et al. 2013). Could these snoRNAs direct 2’O-methylation on mRNAs with an effect in cancer? On the other hand, we cannot exclude the
possibility that rRNA 2’-O-methylations are heavily involved in these diseases. Contrary to the
notion that epigenetic regulation is considered part of transcriptional regulon, which in general
has high level of variability between different organ tissues, epitranscriptomic modifications
have not been widely explored in a similar way regarding ribosomal activity. SnoRNA
expression levels have been known to exhibit distinct patterns under stress and disease
conditions (reviewed in Stepanov et al. 2015). It is possible that rRNA 2’-OMe sites are
dynamic, rather than static, features that can contribute to a layer of regulation during translation.
Owing to potential complex interactions, it is possible that differential methylation of rRNAs
might enable regulation of specific genes or subsets of genes. This notion is echoed in Xue &
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Barna (2012), who proposed a model of dynamic ribosome biology. More interestingly, further
investigation into ribosomes from within a single cell line revealed specialized ribosomal
complexes, which have specific ribosomal protein compositions, and are active in translating a
subset of messenger RNAs (Shi et al. 2017). It was further corroborated by the new evidence that
rRNA sequences between different rRNA clusters are in fact different, rather than just repeats of
the same sequences, suggesting potentially different binding affinities for various protein, RNA
interaction partners (Kim et al. 2018).
SnoRNA-guided 2’-O-methylation has been shown to be easily reconstituted in vitro without
needing a long list of factors, suggesting that snoRNPs may be functional wherever they are
localized within the cell. An ex-vivo study in Xenopus oocytes by injection of branch point 2’-Omethylated pre-mRNAs showed strong preference of alternative splicing using cryptic branch
points (Ge et al. 2010, Galardi et al. 2002). This report certainly demonstrated possible
nucleoplasmic functions of RNA-guided 2’-O-methylation.
The Prader-Willi critical region locus on chromosome 15 q11-q13 represents one of the most
complex genomic regions that exhibits extensive splicing, anti-sense transcription and
imprinting; this region is associated with the neurodevelopmental diseases Prader-Willi
syndrome (PWS) and Angelman syndrome, but the exact molecular basis of the diseases has not
been clearly understood (Figure 6, Chamberlain et al. 2010 and references therein). Within this
locus are two clusters of orphan box C/D snoRNAs, the SNORD115 (H/MBII-52) and
SNORD116 (H/MBII-85) clusters (Cavaillé et al. 2000, Bortolin-Cavaillé & Cavaillé 2012,
reviewed in Cassidy et al. 2012). SNORD115 was identified as a brain-specific and imprinted
snoRNA cluster (45 identical snoRNAs) and was predicted to target the serotonin receptor 5HT2RC gene through sequence complementarity. This predicted target coincides precisely with
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known ADAR editing sites on the serotonin gene. Subsequent studies demonstrated that 1) The
SNORD115 snoRNAs form canonical snoRNPs. 2) Expression of SNORD115 inhibits ADAR2
editing of the serotonin receptor. 3) These snoRNAs influence exon inclusion decision on 5HT2RC (Vitali et al. 2005, Kishore & Stamm 2006). The SNORD116 cluster of 30 closely
related snoRNAs is always deleted in PWS patients, but no targets have been identified (Bieth et
al. 2015).
Although no processed sno-miRNAs are found for SNORD116 cluster, two unusual RNA
species are transcribed from the region: sno long non-coding RNAs (sno-lncRNAs), where a
lncRNA is flanked by two snoRNA ends; and 5’-SnoRNA capped and 3’-PolyAdenylated (SPA)
lncRNAs (SPA LncRNAs) (Yin et al. 2012, Wu et al. 2016). Unlike snoRNAs, sno-lncRNAs
have predominantly nucleoplasmic localization and contain multiple binding sites for the
splicing factor RBFOX2, a protein that is known to regulate alternative splicing. Both snolncRNAs and SPA lncRNAs can form nuclear aggregations that trap at least RBFOX2 and two
other proteins, and it has been proposed that the two lncRNAs function as sponges to sequester
splicing factors and thus disrupt some normal splicing processes (Yin et al. 2012, Wu et al. 2016,
reviewed in Li & Fox 2016). Although RBFOX2 overexpression in tissue culture affected the
inclusion of a number of alternative exons as reported from sno-lncRNA study, the physiological
relevance of the sequestration model remains to be validated. Interestingly, RBFOX2 has
recently been reported to have a role in attenuating global Polycomb Complex II activity,
suggesting that the sno-lncRNA and SPA-lncRNAs may affect more than splicing (Wei et al.
2016). It is still not resolved whether, SNORD116 snoRNAs can behave similarly to SNORD115
in terms of effects on splicing, or whether SNORD115 or SNORD116 induced 2’-O
methylations on specific targets contribute to PWS.
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Figure 6. Diagram for the genomic locus of the Prader-Willi Syndrome critical region.
Anti-sense transcription is paternally silenced. Solid arrow represents the broad transcription activity that
is common in most cell types. The dashed blue arrow represents the UBE3A antisense transcript that is
only generated in neurons. UBE3A transcription from the sense strand is maternal allele specific in
neurons, while bi-allelic transcription occurs in other cell types. Dashed brown lines indicate the
minimum deletion region associated with PWS patients (Bieth et al. 2015).
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So far, I have detailed numerous possible links between 2’-O-methylation and various
observations. Although the report of viral mRNA internal 2’-O-methylation is promising (Dong
et al. 2012), there remains a significant lack of direct evidence of the existence of 2’-Omethylation on sites/genes of interest other than on rRNAs or snRNA. We can now clearly see
the benefit of obtaining the methylation landscape, be it aiding in characterization of orphan
snoRNAs, or investigating whether presence of a 2’-OMe correlates with splicing processes or
studying methylation variability. It would allow us to study the modification more purposefully
instead of relying on the chance of serendipitous discovery of new sites and/or potential
functions.
D. Insights into 2’-OMe in other organisms.
Like human, the mouse also expresses a large number of snoRNAs. Consistent with the
conservation of snoRNA machinery, not only snoRNP mechanisms are highly similar, introns of
mouse snoRNA host genes are highly homologous to those of human counterparts despite much
greater variation in the exons of the respective host genes (Ganot et al. 1999, Yoshihama et al.
2013, Tanaka-Fujita 2007). Therefore, rodent samples have been used extensively in conjunction
with human and yeast samples for many of the discoveries made in the field. Since mouse
samples are more readily available compared to other higher eukaryotes while also being
genetically and physiologically closer to human than most other model organisms, it could be an
even more powerful tool now for snoRNA and 2’-O-methylation studies as we investigate
further into the disease aspect of the snoRNA machinery.
Some distantly related non-higher eukaryotic organisms exhibit particularly high levels of 2’O-methylation and the significance, besides less extensively studied, of this is also not yet clear.
T. brucei is a protistan parasite causing deadly disease in sub-Saharan Africa – the African
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sleeping sickness-. During its life cycle the parasite shuttles between its tsetse fly vector and its
human host where it lives freely in the bloodstream (reviewed in Ponte-Sucre 2016).
Trypanosomes possess 21 snoRNA clusters that are responsible for producing more than 90
snoRNAs, of which 57 are box C/D. It was suggested by bioinformatic mapping and partial
experimental validations that there are more than 130 2’-OMe rRNA sites in Trypanosome
brucei (Uliel et al. 2004, Liang et al. 2005). Interestingly, differential methylation on the rRNA
has been reported on two different life cycle stages of the organism. Consistent with the earlier
mentioned dynamic ribosome model, the differential methylation detected was not a change in
the overall level, but rather, changes in specific sets of sites (Barth et al. 2008). Differential
pseudouridylation has recently also been implicated in this transition (Chikne et al. 2016). The
authors have inferred from thermophilic organisms, many of which have high numbers of 2’-Omethylation sites, that the differential pattern could be a way help coping with increased
temperature going from insect form to mammalian blood stream form. However, this assumption
may rather predict an overall increase in methylation of the rRNA. Further investigation is
required to understand the precise function of the 2’-OMe in T. brucei. Systematic profiling of
the sites could be a starting point, followed by biophysical and other studies to determining their
structural contributions, as well as whether they are involved in additional functions. Since T.
brucei is a rather remote organism from higher eukaryotes in the evolutionary tree, studying it
would also aid in further comprehension of the robustness of the regulatory roles of the 2’-OMe
in human.
E. Methods to study 2’-OMe.
2’-OMe sites were traditionally detected using one of four strategies. The first strategy
employs primer extension. The primer extension experiment utilizes polymerase pausing effects
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when obstacles are encountered during extension. Such an effect is amplified when the
experiment is carried out under limited dNTP concentrations, especially when encountering
secondary structures and some bulky modifications. If RNA gel electrophoresis is performed on
these primer extension products, bands corresponding to sites of polymerase stoppage can be
seen. Thus, to detect/validate a suspected site, a downstream primer can be designed, and a
primer extension experiment can be carried out (Figure 7A, Maden et al. 1995). A second
method is based on the fact that ribose methylated bases are resistant to alkaline hydrolysis. If an
RNA pool, such as total RNA, is hydrolyzed to shorter fragments, it is expected for any
methylated RNA that hydrolysis will occur at every position except for the site of the methylated
base. RT can then be performed with a primer specific to a transcript suspected to have 2’-OMe.
The RT product is then visualized on a gel together with a sequencing ladder. For example, if
only a base 150bp upstream of the primer is 2’-O-methylated, a fragment of 150bp would not
exist after partial alkaline hydrolysis, and this would correlate with a gap at that base on a
sequencing gel (Figure 7B, Kiss-László et al. 1996). A third method was developed based on the
observation that RNaseH cleavage strictly requires perfect pairing between DNA and RNA
molecules. For a suspected 2’-OMe site on human 18S rRNA for example, a short DNA oligo
can be designed to hybridize to the region. After RNaseH digestion, visualization on a gel should
show either presence or absence of the digestion products depending on whether the methylation
indeed occurs at the region (Figure 7C, Yu et al. 1997). A final method is to purify a subset of
RNA transcripts that are of interest and subject them through liquid chromatography and mass
spectrometry after fragmentation into proper sizes (Qiu & McCloskey 1999).
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Figure 7. Illustrations of conventional methods used for 2’-OMe detections and validation.
(A) Low dNTP Primer Extension. Each RNA diagram represents different transcripts with different 2’OMe sites. Gene-specific primers are designed for targets of interests. Under low dNTP concentration, 2’OMe is enough to induce significant amount of pausing of the polymerase extension, resulting in a
product pool with major species as the paused fragments.
(B) Alkaline Hydrolysis. Sequences in the diagram are multiple copies of one RNA transcript form of a
hypothetical gene. Red-color highlighted bases are 2’-O-methylated. Because 2’-O-methylated bases are
resistant to alkaline hydrolysis, the digestion cannot occur at 3’- of the 2’-O-methylated U base (the star
labeled sequence). Thus, if the random digested product is reverse transcribed with a gene-specific
primer, and visualized on a sequencing gel, there will be signal for every base that corresponds to
hydrolyzed RNA fragments shown in top right panel. However, there will be a gap at 2’-O-methylated U
position as a fragment from hydrolyzing the U cannot be generated.
(C) RNaseH Assay. 2’-OMe disrupts perfect oligo-RNA annealing, thus preventing RNaseH digestion
from happening. To test whether a several-base region contains a 2’-OMe, a radiolabeled 10bp oligo
targeting the specific loci can be designed, and RNaseH assay carried out. The digestion product can be
visualized on PAGE gel.
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Methods Used in Detecting sites of 2’-O-methylation.
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Although multiple methods were available for detecting a single modification, major
drawbacks exist. In primer extension under low dNTP conditions, despite observations of
polymerase pausing, 2’-OMe is a much weaker factor compared to RNA secondary structures
and some other modifications that strongly affect base pairing (reviewed in Maden 2001). Such
properties make this method highly prone to false positives for moderately long transcripts. It
could be viable to pinpoint to a small stretch of RNA bases, but even then, one has to be aware of
local secondary structures and other modifications. The RNaseH method is limited as a general
confirmation tool due to its inability to map at single base resolution besides the same factors
plaguing primer extension method also causing uncertainties of any results. The biophysical
method using mass spectrometry remains highly accurate, however, it is also the most labor and
cost intensive method and is unsuitable for the discovery of new sites. Furthermore, all methods
described lack scalability. Although these methods were invaluable in identifying majority of 2’OMe sites on rRNAs, the less than 150 sites total detected were the result of decades long work
and piecing together data from various labs. These methods at their current state are acceptable
for validation purposes, but not suitable for explorative studies.
To address the shortcomings of the conventional methods, two high-throughput strategies
have been developed in recent years. RIM-seq and 2OMe-seq modify the low dNTP primer
extension method and adapt it to Illumina sequencing workflow, thus enabling high -throughput
profiling (Jorjani et al. 2016, Incarnato et al. 2016). Unlike primer extension experiments
mentioned above, RIM-seq and 2OMe-seq use random primers, removing the restriction to the
analysis of single transcripts; the products of primer extension are converted into Illumina
sequencing libraries, sequenced, and analyzed (Figure 8A). However, the disadvantage of nonspecific pausing remains in this approach. In RIM-seq, more than 400 2’-OMe sites were
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identified, at least 200 more than previously known, but it is unclear how many of the novel sites
are true positives owing to the inherent high false positive rate of primer extension. 2OMe-seq
attempts to partially alleviate the issue with the addition of a parallel fibrillarin knockdown
experiment. The KD samples’ mapping should show decrease of signal for sites that are snoRNA
guided. Thus, any sites detected in the non-KD samples that correspond to reduction in KD
samples theoretically represent true sites. However, besides the necessity to double the sample
amount, gene silencing experiments are known to introduce variables (Olejniczak et al. 2009).
Ribometh-seq, on the other hand, combines alkaline hydrolysis with NGS. In this case, the
alkaline hydrolyzed RNAs are directly converted into sequenceable cDNA libraries and
sequenced (Marchand et al. 2016). The premise is that due to randomness of the hydrolysis,
when enough RNA is supplied, there should be hydrolysis at every single position of all RNAs
except for methylated bases. Thus, the presentation of the alignment would show mapped 3’ends on every single base position, while gaps would form on methylated ones (Figure 8B).
Although the method has the advantage of being highly specific, its reliance on negative rather
than positive signals can become an issue when applied to lower abundance RNAs such mRNAs.
In addition, it is viable for rRNAs as there are less than 8kb distance to cover. However, for
human mRNA with average length of about 3kb and around 100000 different types transcripts, a
normal exome RNA-seq requires 30 million reads per sample, translating to 0.09 read per base,
while Ribometh-seq would require 300 reads per-base, or 100 billion reads per sample for
accurate 2’-OMe site calling. The cost for such sequencing effort is unattainable for most
laboratories.
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Figure 8. Available high-throughput methods for 2’-OMe detection.
(A) RIM-Seq/2OMe-seq. Primer extension with low dNTP concentration is carried out with
random primers. The RT cDNA product pool is then converted into a sequencing library. After
sequencing and read alignment, read 5’-end enrichment is calculated for every base position.
(B) Ribometh-seq. RNA is randomly hydrolyzed under alkaline condition. The digested
fragments are converted into sequencing library and sequenced at very high depth. Because 2’O-methylated-base is resistant to hydrolysis, there does not exist any fragment that ends with that
methylated base position. Thus, when read 3’-end enrichment is calculated for every base
position, 2’-OMe site corresponds to the base position lacking read 3’-end mapping.
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F. Thesis Objectives.
As biotechnologies leaped forward in the past decade, the technological barriers preventing
us from accurately and efficiently profile 2’-OMe sites are melting away. As discussed above,
even with recent developments, our ability to accurately and efficiently profile 2’-OMe sites still
remains unsatisfactory. To be able to test the 2’-OMe function centric model, and to answer the
questions we proposed so far, we need a flexible and efficient way of profiling the sites
transcriptome-wide. The main focus of this thesis, thus, will be the development of a highly
specific and accurate high-throughput method detecting 2’-OMe sites. In Chapter II, I will
summarize the strategy we used to selectively enrich 2’-OMe sites and its distinct features
comparing to currently available methods. I will also present the developmental timeline and
optimization steps taken. Finally, tests of these principles on human rRNA sites will be
discussed. In Chapter III, I will discuss the current state of the method, as well as applications of
the method. Due to the highly flexible nature of the method, I will be emphasizing on different
directions we can take to improve and adapt the method in Chapter VI.
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Chapter II
Development of Ribose Oxidation Sequencing (Riboxi-Seq) For Profiling 2’-Ome Sites
A. Abstract
RNA modifications, or epitranscriptomic marks, are not only important for basic biological
processes such as nominal ribosomal functions, but also have been implicated in cellular defects
and diseases. Ribose methylation (2'-O-methylation, 2'-OMe) occurs at high frequencies in
rRNAs and other small RNAs and is carried out using at least one shared mechanism across
eukaryotes and archaea. It is one of the epitranscriptomic marks that have been identified to be
involved in many cellular processes without clearly characterized functions. Evidence so far
indicates 2’-OMe being mainly a structural feature, however, due to deficiencies in methodology
studying the modification, there might be more to be learned even on rRNAs. Furthermore, the
possibility of internal 2’-OMe sites on mRNA has been suggested (Dong et al. 2012, Holley et
al. 2015), thus it is important to characterize the landscape of 2'-O-methylation. Here we report
the development of a highly sensitive and flexible method for ribose methylation detection using
next-generation sequencing. A key distinction of this method is to use sodium periodate to enrich
2’-OMe sites, allowing only RNAs harboring 2'-OMe groups at their 3'-ends to be sequenced.
Although currently requiring microgram amounts of starting material, this method is robust for
the analysis of rRNAs even at low sequencing depth. An important feature of the method is that
it can be expanded to work on a transcriptome-wide scale with minimal revision.
B. Background
A great majority of 2’-O-methylations are directed by Box C/D snoRNAs, noncoding RNAs
that guide the modification of target sites via complementary RNA sequences. In humans,
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snoRNAs are assembled into snoRNP particles, containing the conserved core proteins NOP56,
NOP58, 15.5K, and fibrillarin (the catalytic component) (Tycowski et al. 1996; Filipowicz &
Pogači 2002; Watkins & Bohnsack 2012). 2’-O-methylation has been extensively studied for a
number of years with the goal of establishing functional and mechanistic links with specific
biological pathways. Although, early studies demonstrated that 2’-O-methylations on rRNAs are
prevalent during ribosome biogenesis, depleting several snoRNA guides alone or generating
fibrillarin heterozygous mutations does not produce noticeable defects (Newton et al. 2003).
However, homozygous mutations of fibrillarin have been shown to be embryonically lethal in
mouse, thus suggesting that this gene is essential for organism development (Tollervey et al.
1993, Newton et al. 2003). Such evidence strongly suggests that the modification could have
important roles. 2’-O-methylation has also been shown to be present on tRNAs and has been
implicated to be crucial in translational circuitries (Satoh et al. 2000; Guy et al. 2015). A
substantial portion of known methylated sites in rRNA lie in close proximity to ribosome
functional sites such as regions around the peptidyl transferase center, suggesting the potential
involvement of such modifications in rRNA folding, stability, and translation (Decatur &
Fournier 2002). Ribose methylated bases are also found at mRNA caps and are involved in host
pathogen responses (Daffis et al. 2010; Rimbach et al. 2015). Additionally, 2’-OMe adenosines
have been found within, rather than at the cap, of flavivirus RNA transcripts. Homology between
2’-O-methyltransferases of Flavivirus, Dengue-1 and West Nile also suggest a more common
phenomenon (Dong et al. 2012). Furthermore, recent evidence indicates that in addition to being
associated with the 5’ cap, mRNAs might potentially possess internal 2’-O-methylated sites (Lee
et al. 2016, Holley et al. 2015). Thus, currently available data hint that there is an increasing
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possibility that 2’-OMe possesses much more expansive regulatory roles than in ribosome
biogenesis.
The list of known 2’-O-methylation sites is frequently updated, as experimental techniques
evolve and mature. However, until recently, a major hurdle in obtaining a more complete profile
of the 2’-O-methylation landscapes has been the lack of an efficient and reliable modificationspecific and high-throughput detection method. Methylation sites have traditionally been mapped
using targeted approaches including primer extension under limiting dNTP concentrations,
where reverse transcriptase stalls when encountering a methylation site, or resistance to RNaseH
digestion when synthesized DNA oligos are introduced (Yu et al. 1997; Maden 2001). Primer
extension experiments are particularly prone to false positives for detecting 2’-O-methyl sites
due to nonspecific polymerase pausing or secondary structure-induced pausing, while RNaseH
assay lacks base resolution. Most importantly, both methods require laborious mass spectrometry
to validate a detected site (Qiu & McCloskey 1999). Also, neither is suitable for de novo site
detection and high-throughput screening, because the base position needs to be known in
advance for primer or hybridization oligo design. This makes primer extension and RNaseH
assay most useful as confirmation tools. Recently, primer extension, as described in RIM-seq and
2OMe-seq, has been adapted for high-throughput detection of ribose methylation sites by
combining random priming with next-generation sequencing (Incarnato et al. 2016; Jorjani et al.
2016). This study identified over 400 sites, almost 300 more than what have been curated in
human rRNAs (Lestrade & Weber 2006). It is unclear, however, how many of the novel sites are
true positives, owing to an inherent high false-positive rate of primer extension. Although
potential matches to BoxC/D snoRNAs were bioinformatically identified for some of the novel
sites found in the study, methylation could not be confirmed, because there are known snoRNAs
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that interact with targets without guiding the deposition of methyl on ribose (Cavaillé &
Bachellerie 1998; Lafontaine 2015). As a consequence, these sites might not accurately represent
the methylation pattern until they are further validated.
Alkaline hydrolysis is another conventional method used to identify 2’-OMe. Due to the
resistance to hydrolysis of a base modified by 2’-OMe, fragmented RNAs can be reverse
transcribed and gaps correlating to the sites are visualized on gel (Kiss-László et al. 1996).
Although alkaline hydrolysis is very specific to 2’-OMe, the site needs to be known in advance.
Ribometh-seq was developed recently and utilizes the property of alkaline hydrolysis of ribose
methylated bases. Thus, by randomly hydrolyzing RNA and performing next-generation
sequencing at very high depth, there should be uniform coverage of 3’-end positions across
regions of interest except at positions of 2’-O-methylation. This method overall has much better
specificity and accuracy, as it has successfully detected about the same number of sites in rRNAs
as have been annotated. Several novel sites were also validated by mass spectrometry (Krogh et
al. 2016). However, the method relies heavily on negative rather than positive signals. In
addition, the requirement for high read depth and coverage makes such studies costly, and the
method can also suffer from high background noise due to resistance to alkaline hydrolysis of
highly structured regions. In order to address these issues, we have developed a 2’-O-methyl
ribose-specific, high-throughput method, which relies on positive rather than negative signals, to
detect 2’-O-methylation sites.
C. Method development, Methods and Materials
1. Methodology development
Development of an accurate method for 2’-OMe detection is best achieved by utilizing a
modification specific strategy. Unlike other modifications such as m6A and m1A, there is no
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antibody available for 2’-OMe, nor does there exist any 2’-OMe specific chemical modifier that
enables purification. As a consequence, other strategies for enriching 2’-OMe had to be
considered.
Random digestion is a common strategy for Illumina based regular RNA sequencing, as it
reduces RNA transcript to a more uniform length appropriate for the sequencer. The result is that
there will be RNA fragments generated such that each fragment represents 5’- and 3’- ends of a
portion of the original RNA transcript. When mapping these fragments back to the genomic
sequence, a pattern representing distinct 5’- and 3’- ends, each with similar frequency, can be
obtained. Such a property is useful because when combined with more stringent digestion, which
generates shorter fragments, there will be a higher probability that a random base will be present
at 5’- or 3’- end of a fragment (Figure 9A). Ribometh-seq for example exploits this particular
chemistry together with ribonucleic acids’ resistance to hydrolysis if 2’-O-methylated, thus
producing a sequencing pattern where appearances of negative signal are dictated by probability.
However, to achieve a positive signal, resistance to hydrolysis is not enough, because 2’-Omethylated ends can never exist in the digestion product due to their resistance. The closest that
random degradation can achieve is 1 base upstream of the 3’-end of a fragment (Figure 9A). To
ensure that 2’-OMe sites are represented at the ends of the fragments at all, it is necessary to
remove at least 1 nucleotide either from the 3’-end. Removing more than 1 base, which will be
discussed later, can greatly increase sensitivity, although it can make the procedure rather
laborious. Through literature searches, we found a stepwise strategy to degrade RNA base by
base that has been available since the 20th century. In this strategy Alefelder et al. (1998) first
oxidized RNA 3’-ends using sodium periodate (NaIO4), which have 2’- and 3’- OH groups (cisdiols), into 2’-, 3’- dialdehydes. Such dialdehyde structures are prone to β-elimination, which
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removes the oxidized RNA terminal oligonucleotides. The resulting products will contain
terminal 2’-O-methylated bases with 3’-phosphates and nonmethylated bases with a mixture of
cyclic-phosphates, 3’-phosphates, and 2’-phosphates (Figure 9B).
By extensively hydrolyzing RNAs to sizes smaller than those obtained in the Ribometh-seq
protocol, we speculated that we should be able to generate a pool of RNA fragments that has
sufficient 2’-O-methylated ends to provide grounds for the rest of the procedures. However,
instead of -OH groups at 3’-terminal bases’ 2’-ribose positions required by oxidation, alkaline
hydrolysis produces 2’- phosphate groups. To simplify our pilot experiments, we found a
commercially available enzyme called Benzonase nuclease, which is both an endonuclease and
an exonuclease, and which generates cis-diols when used for digestion (Figure 9C, SigmaAldrich). Benzonase nuclease, unlike most other RNAses, does not have a sequence bias.
Therefore, we expected digestions with Benzonase to behave similarly to alkaline hydrolysis.
With 2’-OMe exposed, we next sought to enrich these ends. Conveniently, 2’-O-methylated
bases have been shown to be resistant to NaIO4 oxidation we used for beta elimination. This
could serve as a perfect strategy to convert all non-methylated ends into dialdehydes while
keeping 3’-terminal bases with 2’-OMe intact. Indeed, an earlier publication on a quick ligation
protocol used this property to convert un-ligated products, which have cis-diols at their 3’terminal ends, into dialdehydes to enrich ligated products that have unreactive 3’-ends (Kirino &
Mourelatos 2007, Kurata et al. 2003). The oxidized RNA fragments should then be ready for
sequencing library preparation, which requires ligation of a linker to the fragments’ 3’-ends in
order for subsequent conversion into cDNA using RT. Because fragments with dialdehydes at
their 3’-termini are incompatible with ligation, only the ones that have terminal 2’-OMe groups
are converted into the cDNA library. PCR amplification can then be performed to generate the
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final library that is labeled with sequences recognized by the Illumina sequencer, which was
introduced with the PCR primers (Figure 9D).
18S rRNA (SSU) and 28S rRNA (LSU) add up to about 7kb in length, where there are
around roughly 150 known 2’-OMe sites, averaging around 1 2’-OMe per 50 bases. Depending
on the efficiency of 2’-OMe site exposure after fragmentation and beta elimination, we expect
the final terminal 2’-OMe numbers to be relatively low. As a consequence, one caveat of the
proposed library preparation strategy is that after oxidation, the number of fragments available
for ligation and conversion into sequenceable reads might become too small without having to
drastically increasing starting materials. Two potential issues can occur: first, extremely small
quantities in general are hard to quantify; second, PCR preferential amplification can greatly
alter original ratios between different fragments. The first problem can be addressed by
increasing PCR cycles, however, this worsens the PCR bias outcome. To remedy these issues,
we include a random sequence portion into the RT primer. In general, digestion of RNA does not
generate fragments with exactly the same 5’ and 3’ ends. Thus, if two sequenced reads have
exactly the same RNA portion and same random sequence, these are most likely generated from
PCR amplification, and are thus duplicates. The inclusion of the random sequences allows us to
remove these PCR duplicates during data processing, thus reducing the overall bias of the
procedure while keeping the starting material amount relatively low (Figure 10A).
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Figure 9. Chemical principle of the RibOxi-seq.
(C) Property of random digestion. In theory, every base position of an RNA transcript can be
cleaved, generating fragments with variable 3’-ends. These 3’-ends cannot contain 2’-Omethylated bases as explained earlier in the thesis. The bottom left panel represents the type
digestion products where a 2’-OMe is 1 nucleotide upstream of RNA 3’-end, which is the species
concerned in the method. The right panel shows other possible background RNA species.
(D) β-elimination. Elimination of one 3’-terminal nucleotide for exposure of 2’-OMe.
(E) Random Digestion strategies. RNA transcripts hydrolyzed under alkaline condition
generate fragments with 3’-phosphates, which require extra steps before elimination can be
performed. On the contrary, Benzonase digested fragments possess the cis-diol structure that is
directly compatible with elimination.
(F) Enrichment of terminally methylated RNA fragments. RNA mixture obtained from βelimination is undergone NaIO4 oxidation a second time. Because fragments with terminal 2’OMe are protected from oxidation, only non-methylated fragments are converted into dialdehyde ends. Subsequently, only fragments protected by 2’-OMe can be converted into
sequencing library and sequenced.
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The sequencing reads obtained from the Illumina sequencer first need to be analyzed to
remove PCR duplicates discussed above followed by trimming to remove the random sequences,
as well as the linker sequences introduced during ligation. The processed reads can then be
aligned to a reference genome. The 3’-terminal bases of the aligned reads correspond to the
original RNA 2’-O-methylated 3’-ends. We speculated that by counting these ends, we would be
able to see a pattern that is largely consistent with the distribution of known 2’-OMe sites (Figure
10B).
In order to statistically evaluate the results, a control group for each sample is needed. To
properly control for the method, we proposed to have additional samples undergo exactly the
same procedures except for the oxidation step. Such preparations of the control samples should
not show enrichment of 2’-O-methylated ends, thus generating a relatively uniform alignment
pattern across the reference genome. On the contrary, they should show a lack of ends mapping
to 2’-OMe sites reminiscent to the principles of Ribometh-seq (Figure 8B, Figure 10B).
Subsequently, end-counting data can be analyzed using DESeq2, a bioinformatic tool for
differential expression analysis. DESeq2 compares control data, where ends are distributed
evenly, with oxidized data, where ends align at specific positions. The program uses a negative
binomial statistical model to evaluate the differential between the two and assigns significance
values, as well as computing log2 fold changes for every position (Figure 10B, Love et al. 2014).
We would then be able to examine data and determine the optimum cutoff for 2’-OMe sitecalling.
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Figure 10. Continuation of RibOxi-seq
(A) Library preparation and PCR duplicates removal strategy. Random hexamer sequence
is introduced as part of the RT primer. After PCR amplification, any identical ends together with
identical random sequence is considered PCR duplicate and can be removed later
bioinformatically.
(B) RibOxi-seq data processing, analysis and visualization. Enrichment of read 3’-ends at
sites of 2’-O-methylation (bottom left panel). When counting just 3’-ends, the data can be
visualized in top right panel.
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To summarize the key principles of the proposed method: first, fragmented RNAs containing
3’-ends that are either unmethylated or 2’-O-methylated are obtained using random digestion
followed by β-elimination; then, an oxidation step renders the nonmethylated ends incapable of
ligation to linkers used for high-throughput library construction; after sequencing, the reads are
aligned to a reference genome and only positions of the 3’-ends of aligned fragments are counted
and displayed for each base position; the count data for oxidized and nonoxidized samples are
then normalized, compared, and analyzed using DESeq2 for single-base resolution methylation
site determination. The major difference between our method and currently available methods is
its specificity and its reliance on positive rather than negative signals. The cis-diols of non-2’-Omethylated ribose are converted into dialdehydes using NaIO4, thus preventing them from being
ligated to linkers for sequencing library construction. The advantage of this step over alkaline
hydrolysis is that Benzonase leaves terminal ends with 2’-OH instead of phosphate group, thus
eliminating an extra dephosphorylation step.
Before starting the pilot experiments, it would be to our advantage to determine whether
Benzonase nuclease is able to cleave at 2’-O-methylated bases, removing the requirement of
eliminating a 3’-terminal base. To test this, we designed an oligo that is fully methylated. A
digestion of the oligo shows that Benzonase does not cut at 2’-O-methylated bases (Figure 11A).
Therefore, β-elimination is still required.
We started our experiment by optimizing Benzonase nuclease digestion through time course
and temperature gradients with PA1 cell total RNA. Benzonase rapidly degrades RNA within
minutes at room temperature, leaving little room for optimization. Thus, all digestions were
carried out on ice. The aim was to obtain the smallest fragments without exceeding the lower
detection limit of the Agilent TapeStation (25bp), which is an imaging system that allows very
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fast visualization and quantification of nucleic acids. Several digestion time courses helped to
determine our target sizes to be an average of 70bp (Figure 11B).
Next, we proceeded with β-elimination. As mentioned earlier, the reaction leaves a mixture
of terminal cyclic-phosphates, 3’-phosphates, and 2’-phosphates on non-methylated fragments.
To enrich methylated ends, oxidation is required to inactivate non-methylated ends, which
require terminal cis-diols. Thus, a phosphatase treatment was necessary. Most available
phosphatases, such as calf intestine alkaline phosphatase, are only active in removing 3’phosphates. If used, nonmethylated bases with 2’-phosphates would survive the oxidation step
and generate false-positive signals in sequencing. To prevent this phenomenon, T4
polynucleotide kinase (T4 PNK) was used. Although less efficient than other widely used
phosphatases, the advantage is that this enzyme nevertheless is capable of removing all three
types of phosphates under acidic conditions in the absence of ATP (Cameron & Uhlenbeck 1977,
Das and Shuman 2013, Kirino & Mourelatos 2007). It has been shown that T4 PNK's
phosphatase activity is sufficient to remove the majority of the phosphates in <40 min at 37°C
(Honda et al. 2016). Since RNA fragments with phosphates can generate bias in subsequent
steps, we have increased enzyme concentration and extended incubation time to 4 h. With proper
end treatment, the mixtures generated after β-elimination and T4 PNK treatment contain
fragments with ends of either cis-diol or 2’-OMe,3’-OH.
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Figure 11. Protocol optimization
(A) Confirming Benzonase inability to cleave at site of 2’-OMe. 50bp RNA oligo is designed
to have locked DNA bases except for the 4 2’-O-methylated RNA bases in the middle. Digestion
using Benzonase was visualized on Agarose gel (top) and tapestation (bottom).
(B) Digestion time course. Bottom panel represents the size distribution corresponding to the
last lane in top panel with 75min digestion time.
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After another NaIO4 oxidation treatment, we needed to ligate a linker to provide sequence
complementarity for subsequent reverse transcription primers. Different variants of the T4 RNA
ligases are known to have different reactivities toward different substrates and some of them
generate bias toward certain base identities. Our goal was to minimize sequence bias during the
ligation step and also maximize efficiency. It has been shown that both T4 RNA ligase I and II
are biased against 2’-O-methylated bases, while ligase I has further bias against 2’-OMe-U
(REF). Under optimized condition however, T4 RNA ligase II is able to ligate pre-adenylated
linkers to RNA with 2’-OMe ends at acceptable efficiency, while displaying almost no base
identity bias (Munafó & Robb 2010, Zhuang et al. 2012, Raabe et al. 2014). We thus followed
the available optimized protocol to ligate 3’- linker. A 5’-linker is then ligated prior to reverse
transcription for PCR primer annealing in a later step. We then tested both 5’ and 3’ ligation
using primers complementary to the ligated linkers and showed that ligation was successful. At
this step, we wanted to have at least partial confirmation that the basic chemistry works before
finishing the library preparation and proceeding to sequencing. We designed 3 rRNA forward
primers at distinct locations and PCR amplified the cDNAs of both control and oxidized samples
with RT primer as reverse primer. We observed a continuous smear in controls while oxidized
samples displayed distinct bands, consistent with the notion that fragments should have a
uniform distribution in control but ends accumulating only on methylated positions in oxidized
sample (Figure 12). The validation encouraged us to proceed with final steps of library
preparation and subsequent sequencing.

69

Figure 12. Library validation using PCR
Refer to main text for details
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The initial sequencing was done with 2 biological replicates for each control and oxidation
experiments on Illumina MiSeq sequencer, which generated a minimum number of reads.
Although low read counts may negatively affect accuracy, this was enough for a proof-ofprinciple experiment. Sequencing results were analyzed with a custom bioinformatic pipeline,
which is presented at the end of this Chapter. Comparison of our data with available 2’-OMe
databases was performed, to ensure our goal was achieved, prior to increasing to 3-replicates per
sample and switching to the Illumina NextSeq platform, which generated 5 times more data.
2. Cell culture and RNA extraction
RNAs used in the initial experiments described in this chapter were extracted from the
human ovarian cancer PA1 cell line and HEK 293T cell line. Both cell lines were cultured using
regular DMEM 1X media supplement with 10% FBS as well as 1x Penicillin-Streptomycin in
15cm Petri dishes. Cells were lysed on the dish when reaching confluency with lysis buffer from
PureLink® RNA Mini Kit followed by RNA extraction and on-column DNase treatment
according to the manufacturer’s protocol. Total RNAs used in the WT vs. KO experiments were
extracted from either wild type, U32 snoRNA KO or U32+U51 snoRNA double KO 293T
provided by the Holley lab at Duke University.
3. PCR validation of cDNA
Forward primers for 3 distinct 18S rRNA locations were used in conjunction with RT primer
to amplify 1 µL of cDNA obtained from reverse transcription during the RibOxi-seq protocol.
Additional 11.5 µL H2O and 12.5 µL NEB OneTaq master mix was used for the reaction per
manufacturer’s protocol. Extension time was set to 10 seconds due to the short nature of the
templates. The PCR product was run on a 1.5% agarose gel for 2 hrs.
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4. Anti-sense oligo (ASO) knock down of U63 snoRNA
ASOs targeting 2 regions of the snoRNA were designed and ordered from IDT. PA1 cells
were cultured as described above. When cultures became confluent, KD was performed using
Lipofectamine 2000 following the manufacturer’s protocol. Sample setup was: 2 biological
replicates for both ASO1, ASO2 and scrambled KD. RNA extractions were performed 48hr post
transfection using PureLink RNA mini kit. Knock down efficiency was evaluated by qPCR using
miScript II RT Kit and miScript miRNA PCR array kit (Figure 13). RNA was then used in
RibOxi-seq once KD had been confirmed.
5. Radioactive primer extension
For novel site validation, primers were 32P labeled. One microgram of total RNA, 1 µL (10
µM) labeled RT primer, 1 µL 100 µM or 1 µL 10 mM (control) concentrations of dNTPs, 7 µL
of water were denatured at 65°C for 5 min, then chilled on ice. An RT Master mix (10 µL per
reaction) containing 2 µL 10× RT Buffer, 1 µL (40 U) RNase Out, 1 µL AMV RT (NEB), and 6
µL water was prepared, and added to the RNA/primer mix. Incubation was at 42°C for 45 min.
Reactions were ethanol precipitated and resuspended in loading buffer for TBE-PAGE
electrophoresis. This experiment was performed for three selected sites from RibOxi-seq:
positive control at 28S C1880 (lanes 1,2), known but not detected 18S U1668 (lanes 4,5) and
newly detected and not previously reported 28S A3717 (lanes 6,7). The first lane of each set is a
negative control where primer extension was performed with a higher dNTP concentration. The
second lane of each set was performed at low dNTP concentration to promote polymerase
pausing at sites of 2’-OMe.
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Figure 13. QPCR verification of U63 KD efficiency.
U63_1 and U63_2 represent two U63 specific ASO used for KD. Non-specific KD was carried
out using scrambled ASO.
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D. Results
1. RibOxi-seq accurately identifies annotated 2’-O-methylation sites within 18S and 28S
rRNAs.
RibOxi-seq was used to analyze total RNA from the human ovary teratoma-derived PA1
cell line. Site detection was filtered by a combination of log2 fold change and adjusted P-value
from the DESeq2 output. All site-annotations and numbering correspond to the hg19 reference
genome. The lists of known sites we used were curated as previously described (Krogh et al.
2016). By applying a cutoff value of log2 fold change of >7 and adjusted P-value of <0.0001, 39
out of 40 known 18S sites and 60 out of 66 known 28S sites were detected with high confidence
(Table 3, Table 4). The filters were set to correspond to the known sites that have the lowest log2
fold changes and the highest P-values to allow maximum sensitivity (Figure 14). The number of
high confidence sites consisted of 93.3% known sites, which include sites newly found and MS
validated by Krogh et al. (2016) using Ribometh-seq. Using such cutoffs, only three novel sites
(18S: U354, 28S A1322, and A3717) were found. However, when filters were slightly relaxed to
log2 fold change of >6 and adjusted P-value remained unchanged, eight total potential novel
sites were identified (Table 4). Among these candidates, A3717, which displays both a very high
log2 fold change (∼10) and a low adjusted P-value (∼1.5 × 10−13), in 28S was validated using a
primer extension under restricted dNTP concentration (Figure 15). Blasting A3717 in
combination with surrounding bases within the snoRNA database resulted in two potential
snoRNA guide hits, HBII-180B and U37, whose guides are complementary to this region and
fulfill criteria for methylation at the fourth or fifth base of the rRNA complementary sequence.
Although these two snoRNAs were previously noted to also methylate other positions within
28S, snoRNA-guided methylations of multiple targets is known to occur (van Nues et al. 2011).
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As only a few novel sites of methylation in rRNAs in human have been characterized within
recent years, this result argues that the RibOxi-seq method not only identifies known 2’-OMe
sites, but also allows the discovery of new ones.
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Table 3. List of 2’-O methylation sites found in 18S and 28S rRNA from PA1 cells
18S:
chrUn_gl00022 Base
position
0

Base

snoRNAs

Novel?

Detected?

log2FC

adjusted p value

coordinate
109104

27

A

U27

no

yes

17.92943

3.43E-36

109176

99

A

U57

no

yes

12.66704

1.68E-191

109193

116

U

U42A/B

no

yes

12.43167

2.18E-69

109198

121

U

mgh18S-121/Z17B

no

yes

14.57216

3.9E-249

109236

159

A

U45A/C

no

yes

9.515039

6.76E-08

109243

166

A

U44

no

yes

12.78353

3.81E-12

109249

172

U

U45A/B

no

yes

10.19354

1.51E-11

109251

174

C

SNORD45C

no

yes

11.79013

5.83E-73

109505

428

U

HBII-202

no

yes

9.514961

5.07E-69

109513

436

G

HBII-429

no

yes

7.66968

1.64E-45

109539

462

C

U14A/B

no

yes

12.0917

9.85E-34

109545

468

A

SNORD83A/68

no

yes

12.55015

4.02E-50

109561

484

A

U16

no

yes

11.59956

1.64E-25

109586

509

G

HBII-95/B

no

yes

7.985352

3.07E-10

109589

512

A

HBII-234

no

yes

12.83362

1.98E-74

109594

517

C

U56

no

yes

14.91788

2.85E-71

109653

576

A

HBII-336

no

yes

13.86214

9.17E-81

109667

590

A

U62A/B

no

yes

10.33406

6.34E-10

109679

601

G

HBII-251/U103/B

no

yes

12.56987

1.75E-22

109704

627

U

HBII-135

no

yes

9.429529

3.18E-12

109721

644

G

U54

no

yes

12.67708

9.15E-18

109745

668

A

U36A/B

no

yes

11.75379

3.81E-16

109760

683

G

HBII-108/B

no

yes

14.08851

2.06E-51

109874

797

C

ZL107/GGgCD20

no

yes

9.685468

2.90E-63

109876

799

U

U105/B

no

yes

10.46362

5.47E-06

109944

867

G

HBII-419

no

yes

10.21481

2.95E-46

110108

1031

A

U59A/B

no

yes

7.713374

2.73E-05
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110349

1272

C

HBII-142

no

yes

7.509314

7.58E-14

110365

1288

U

HBII-55

no

yes

12.14759

4.76E-68

110403

1326

U

U33

no

yes

8.592145

4.66E-07

110405

1328

G

U32A

no

yes

8.730437

1.33E-06

110460

1383

A

SNORD30

no

yes

11.30044

1.58E-19

110468

1391

C

U28

no

yes

14.38748

2.14E-42

110519

1442

U

U61

no

yes

8.874819

3.31E-11

110524

1447

G

SNORD127

no

yes

11.02978

3.65E-119

110567

1490

G

U25

no

yes

9.173948

4.75E-09

110745

1668

U

Unknown

no

no

110755

1678

A

U82

no

yes

12.47255

5.01E-51

110780

1703

C

U43

no

yes

11.16467

9.52E-40

110881

1804

U

U20

no

yes

13.96577

2.07E-79

28S:
Base
position

Base

snoRNAs

Novel?

Detected?

log2FC

adjusted p
value

113745

397

A

U26

no

yes

8.330468

5.02E-34

113747

399

A

U81

no

yes

12.62798

5.39E-41

114663

1315

G

U21

no

yes

9.655468

2.27E-52

114670

1322

A

yes

yes

7.772448014

1.46E-46

114673

1325

A

U18A/B/C

no

yes

11.56306

1.42E-40

114687

1339

C

U104

no

yes

8.451424

8.58E-20

114869

1521

G

snR39B

no

no

114871

1523

A

U32A/B/U51

no

yes

10.86955

1.06E-20

114881

1533

A

U77/U80

no

yes

8.162373

1.46E-07

114972

1624

G

U80

no

yes

11.99951

1.80E-38

115107

1759

G

no

yes

9.31923

1.37E-25

115218

1870

A

no

yes

10.96471

4.15E-14

chrUn_gl000
220
coordinate

U38A/B

79

115228

1880

C

no

yes

10.55289

7.79E-34

115639

2291

C

U48

no

no

115698

2350

C

U24

no

yes

9.587046

8.89E-23

115710

2362

A

U76

no

no

115712

2364

C

U24

no

yes

11.3781

2.84E-77

115748

2400

A

HBII-202

no

yes

9.007025

2.18E-26

115762

2414

U

ZL5/6/SNORD143/144

no

yes

11.36035

2.97E-23

115769

2421

C

mgh28S-2409

no

yes

13.18647

6.38E-171

115771

2423

G

mgh28S-2411

no

yes

10.01012

3.45E-17

116134

2786

A

HBII-420

no

yes

7.649203

6.31E-05

116151

2803

C

U55

no

yes

8.838489

1.27E-79

116162

2814

A

U95

no

yes

12.29032

7.88E-34

116171

2823

C

U95

no

yes

10.82754

1.51E-60

116184

2836

U

U34

no

yes

11.68902

7.29E-20

116208

2860

C

U50

no

yes

11.05747

9.81E-28

116223

2875

G

U50

no

yes

9.26956

1.08E-19

116974

3626

G

no

yes

11.41354

1.91E-47

117049

3700

C

HBII-180A/B/C

no

yes

11.8941

1.28E-35

117065

3717

A

HBII-180B

yes

yes

10.24109708

1.54E-13

117067

3719

A

U37

no

no

117071

3723

A

U36C

no

yes

10.50822

2.07E-14

117091

3743

G

HBII-276

no

yes

6.466373

5.50E-09

117107

3759

A

U46

no

yes

8.50116

4.32E-10

117132

3784

A

U15A/B

no

yes

10.15055

8.93E-11

117139

3791

G

SNORD15A

no

yes

10.0732

1.37E-29

117155

3807

C

mgU6-77

no

yes

6.963681

3.84E-23

117165

3817

U

ACA48/HBI-43

no

yes

12.21898

1.79E-45

117172

3824

A

U30

no

yes

11.44786

5.37E-33

117177

3829

A

U79

no

yes

13.18303

1.53E-54

117188

3840

C

U74

no

yes

13.59508

9.18E-208
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117214

3866

A

HBII-316

no

yes

10.11454

4.60E-95

117216

3868

C

U53

no

yes

11.55245

3.30E-129

117234

3886

C

U47

no

yes

9.185954

5.57E-10

117246

3898

G

HBII-99/B

no

yes

10.27247

1.36E-30

117272

3924

U

U52

no

yes

9.274559

1.51E-11

117291

3943

G

HBII-82/B

no

yes

12.25001

1.73E-127

117391

4043

G

U102

no

no

117401

4053

C

U75

no

yes

8.835343

1.99E-05

117543

4195

G

U31

no

yes

12.39906

5.00E-31

117574

4226

U

U58C

no

yes

9.428109

4.73E-32

117575

4227

G

U58A/B/C

no

yes

10.08335

1.34E-49

117653

4305

U

U41

no

yes

11.59332

8.11E-19

117717

4369

G

U60

no

yes

9.848911

1.48E-13

117739

4391

G

snR38A/B/C

no

yes

10.2434

6.89E-19

117803

4455

C

U49A/B

no

yes

11.95609

2.11E-135

117841

4493

G

HBII-210

no

yes

10.71001

3.04E-57

117845

4497

U

SNORD62A/B

no

no

117846

4498

G

SNORD62A/B

no

yes

10.83552

5.26E-85

117870

4522

A

U29

no

yes

9.798517

1.09E-12

117883

4535

C

U35A/B

no

yes

12.49586

9.45E-251

117918

4570

A

U63

no

yes

8.764135

7.07E-11

117937

4589

A

SNORD119

no

yes

11.60263

8.32E-131

117965

4617

G

HBII-296A/B

no

yes

8.407214

1.45E-52

117967

4619

U

HBII-240

no

yes

10.46333

1.10E-90

117970

4622

G

U78

no

yes

11.90306

4.03E-95

117984

4636

G

SNORD121A/B

no

yes

9.767133

1.42E-39

Sites determined by filtering DESeq2 analysis output (libraries sequenced on Illumina nextseq)
using log2FC (>6) and adjusted p value (0.0001). Positions highlighted in blue are sites that are
annotated but not detected using our method.
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Table 4. List of potential novel sites found in PA1 cells using RibOxi-seq.
chrUn
position

Base
position

base

snoRNA

Novel?

Detected?

Log2 fold
change

Adjusted p
value

18S:
109431

354

U

yes

yes

8.162207

2.42E-07

109981

904

A

yes

yes

6.712134

1.57E-13

110632

1555

U

yes

yes

6.122584

4.72E-18

114670

1322

A

yes

yes

7.772448

1.46E-46

114671

1323

A

yes

yes

6.73175

3.05E-10

114672

1324

A

yes

yes

6.638669

1.08E-09

yes

yes

10.2411

1.54E-13

yes

yes

6.083689

2.33E-21

28S:

117065

3717

A

117233

3885

G

HBII180B/U37?

18S: U354, 28S: A1322 and A3717 were detected even with stringent filter (log2 fold change
> 7 and adjusted p value < 0.0001), while the rest were found with analysis threshold set to
log2 fold change > 6 and adjusted p value < 0.0001.

2. RibOxi-seq results confirm methylation heterogeneity within the same cell line.
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Among already annotated 2’-O-methylation sites, U4497 and G4498 in 28S are
positioned immediately adjacent to each other. One limitation of the RibOxi-seq method is that if
two sites back to back are both methylated, the site closer to the 5’-end cannot be detected if the
other site is fully methylated. This is because Benzonase (as well as other ribonucleases and
alkali) cannot cleave at the 3’-site of 2’-OMe, so the 5’-site can never be exposed using our
approach. Thus, if G4498 were fully methylated, U4497 would not be detected. Indeed, we did
not see U4497, indicating G4498 may be fully methylated. However, another set of back-to-back
pairs of 28S sites (U4226 and G4227) were both detected with high confidence. The most
probable explanation for our results is that G4227 is only partially methylated, with the
unmethylated population allowing the exposure of U4226 (Table 4). This result is consistent with
the data obtained using Ribometh-seq as well as observations of fractional methylation from
primer extension experiments (Maden 1986; Krogh et al. 2016). Such patterns prompted us to
consider the possibility that annotated 2’-O-methylation sites not detected by our method may be
the result of a complete lack of methylation. To test this possibility, radioactive primer extension
with low dNTP concentration was used to examine the only missing site in 18S, U1668. As
expected, a stop corresponding to that modification site was not detected (Figure 15). It is
interesting to note that this site was also not detected using Ribometh-seq in HeLa cells (Krogh
et al. 2016). Further evidence from more cell lines will be required to confirm whether this site is
actually modified in other cells or tissues.

Figure 14. Volcano plot of the –log10 p value vs log2 fold change.
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Each dot represents a single base position in 18S and 28S rRNAs. Base positions are artificially
filtered by p values and log2 fold changes and color coded. Red dots represent positions with
log2 fold change <= 7 and adjust p value > 10e-7. Teal dots represent log2 fold change <= 7 and
adjust p value < 10e-7. Green dots represent log2 fold change > 7 and adjust p value > 10e-7.
Finally, purple dots represent log2 fold change > 7 and adjust p value < 10e-7. positions labeled
with purple are determined as high confidence sites. Zoomed in view for two regions are
examples to show the actual sites the dots represent. Volcano plot was plotted using R package
ggplot2. The dashed red lines indicate manually set cutoffs.
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Figure 15. Radioactive dNTP concentration dependent primer extension experiment.
The primer extension is performed for three selected sites for RibOxi-seq: positive control at
LSU C1880 (lanes 1 and 2), known but not detected SSU U1668 (lanes 4 and 5) and newly
detected and not previously known LSU A3717 (lanes 6 and 7). First lane of each set is negative
control where primer extension is performed with regular dNTP concentration. Second lane of
each set is performed at low dNTP concentration to allow capture of extension stoppage.
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3. RibOxi-seq requires modest input material but not high sequencing depth.
Accurate determination of sites of 2’-OMe using RibOxi-seq relies not only on peak
calling of oxidized samples, but also on statistical comparison of signals between oxidized and
control lanes. An initial pilot experiment using a small quantity of total RNA in combination
with Illumina MiSeq sequencing generated ∼2.5 million reads for each sample (note: the actual
number of aligned reads was much lower). Upon examining alignment with 3’-end only
reporting, the pattern was strikingly consistent between experiments, with known sites across
18S and 28S rRNAs represented by strong peaks in oxidized samples with corresponding gaps in
control samples mapping to the known sites. After single-base differential expression analysis,
36/40 sites in 18S and 54/66 sites in 28S were detected using a filtering strategy similar to that
described above. However, there were also more than 30 new sites detected (Data not shown).
Those were likely false positives owing to a lack of enough total available control sample 3’base counting reads for DESeq2 statistical analysis. Thus, while promising, this pilot experiment
was not good enough for accurate peak calling. In our experience, highly sensitive and accurate
site detection is achievable at ∼12 million reads (sequencer output) per sample.
4. RibOxi-seq is sensitive to methylation changes that are induced by complete depletion
of specific snoRNA guides.
To validate that our method is sensitive to methylation changes, we performed RibOxiseq on 293T RNA with snoRNA U63 KD. Although U63 directs methylation on 28S rRNA at
position 4541 A, we found no major differences in the methylation status between PA1 and 293T
cell lines. We speculated that this is because KD experiments do not completely deplete
snoRNAs, and it is possible that a small fraction of the total amount is capable of directing
normal levels of methylation. We then sequenced additional samples with either U32 snoRNA
88

KO or U32+U51 snoRNA DKO. U32 is known to direct methylation at both positions 18S
G1328 and 28S A1523, while U51 is known for 28S A1523. Consistently, no 2’-OMe signals
were detected at 18S G1328 for U32 KO sample, and 28S A1523 signal is retained. When both
snoRNAs were knocked out, neither site was detected by RibOxi-seq (Figure 16). these results
confirm the robustness of Riboxi-seq in detecting 2’-OMe sites.
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Figure 16. RibOxi-seq on snoRNA KO 293 total RNA samples.
Track 1 vs. track 2 vs. track 3 vs. track 4. On 18S rRNA, track 1 represents WT sample and has a
strong 2’-OMe peak at position 1328. U32KO and both double KO sample lost that peak.
Track 5 vs. track 6 vs. track 7 vs. track 8. On 28S rRNA, track 5 represents WT sample and has a
strong 2’-OMe peak at position 1523. U32KO also has the same peak present. Both DKO
samples lost the peak.
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E. Discussion
Here we have demonstrated that the principle of using Sodium Periodate to enrich 2’-OMe
sites are feasible. By coupling the chemistry with Illumina RNA sequencing, we successfully
developed a highly sensitive and accurate method to profile 2’-OMe. The wide applicability as
evidenced in experiments using multiple cell lines makes it suitable for both explorative and nonquantitative validation purposes. We verified that the method is sensitive to methylation status
changes through snoRNA KOs, and even showed RibOxi-seq’s capability of detecting
methylation variabilities within a cell line.
Ribose methylation occurs on average about 1 in every 60 nucleotides in 28S and 18S rRNA.
Under such conditions, one round of β-elimination is sufficient for accurate site detection even at
low sequencing depth. However, the occurrence of methylation is very likely to be far lower in
other RNAs such as lncRNAs and mRNAs, and no instances of this modification have been
reported so far in human, other than in 5’-cap structures. In order to detect mRNA modifications,
not only will higher sequencing coverage be required, but also perhaps multiple β-elimination
steps to greatly increase the probability of 3’-end 2’-OMe exposure. Also, additional βelimination can be used on rRNAs if the amount of input total RNA (∼7.5 µg per sample)
described in the standard protocol is impossible to obtain. The required starting material can be
divided by 2–4 for each round of β-elimination added.
Several limitations still exist. Although the number of sequencing reads required is
significantly lower than that for Ribometh-seq, the input RNA material required is in general
somewhat higher, at the micrograms level, with the possibility of reduction to a sub-microgram
level if using additional β-elimination steps. Also, as described above, owing to the nature of
ribose methylated bases being resistant to nuclease and alkaline hydrolysis, it is difficult to detect
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adjacent modified bases if the distal base is fully methylated. Further, exposure of methylated
bases relies on extensive and random digestion. tRNAs and other RNAs shorter than 100 bp are
difficult to study because the sizes of fragments that would need to be generated might be quite
small and difficult to examine. Finally, the method at the current stage cannot be used as a
quantitative tool to compare methylation intensity between different sites, since linker ligation
efficiencies using T4 RNA ligases 1 and 2 have been described to have sequence biases (Raabe
et al. 2014). Hence, without first determining ligation efficiencies of linkers to each of A, U, C,
and G bases using spike-ins of known 2’-O-methylated oligos as internal controls, comparisons
between different sites is not yet possible. On the other hand, comparison between different
samples at the same site appears to be feasible.
F. Complete protocol
The library preparation using our standard protocol requires around 4–6 days to complete with a
moderate work load, factoring out optimization steps. However, the procedure can be stopped
whenever an ethanol precipitation is performed and the sample is resuspended into nuclease-free
water. Alternatively, samples can also be left precipitating in 100% EtOH under −20°C
indefinitely to increase yield.
RNA extraction
For cells cultured in 10 cm Petri dishes, a PureLink RNA Mini Kit is used in conjunction with
the PureLink on-column DNase set to isolate RNA and remove genomic DNA. Steps for the
extraction are detailed in the Purelink Kit's protocol. In case any overexpression system is used,
additional post-extraction gDNA removal may be necessary due to an increase in DNA molarity.
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The TURBO DNA-free Kit has proven effective for such conditions after following its
“Rigorous DNase treatment” protocol.
1. Extract total RNA using the PureLink RNA Mini Kit with PureLink on-column DNase.
2. Optional: Use the Turbo DNase Kit to further remove contaminating DNA.
RNA fragmentation
Each sample set should have at least one control and one oxidation sample. We recommend a
minimum of three technical replicates for each. After completing fragmentation and the
subsequent two steps until just before the oxidation procedure, the RNA loss should be ∼40%. It
is recommended to use an initial total RNA amount of 30 µg (can be lowered upon further
optimization), which will yield about 18 µg of fragmented RNA (results may vary for each
laboratory). The amount of fragmented RNA recommended for oxidation is 4–6 µg, and 1 µg for
nonoxidation. Three technical replicates for all samples require about 15 µg total. The amount of
starting RNA can be significantly lowered if using the alternative procedure during oxidation and
β-elimination steps. Such an alternative is also necessary if applying the method on other
samples depleted of rRNAs.
3. In a 1.5 mL Eppendorf tube, dilute 15 µg of total RNA (for each sample) into 133.5 µL with
nuclease-free H2O.
4. Vortex the mixture and spin for a brief second to collect all liquid at the bottom.
5. Place the tube into a 90°C heat block for 3 min to denature the RNA and immediately place on
ice for at least 1 min.
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6. Dilute 1 µL stock Benzonase (341 U/µL) into 500 U/mL using 681 µL of 1× Benzonase
buffer. (Always dilute fresh prior to using. Do not freeze.)
7. Add 15 µL of 10× Benzonase buffer and 1.5 µL of diluted Benzonase to the diluted RNA
(final RNA concentration: 100 ng/µL). Incubate on ice for 90 min. (This incubation time only
serves as a starting reference since it can greatly vary between different laboratories. Perform a
time-course experiment to establish optimal incubation time based on desired fragment length.)
8. Perform phenol–chloroform extraction. Add 150 µL acid phenol:chloroform and vortex for 10
sec. Centrifuge at 20,000g at RT for 5 min.
9. Transfer about ~150 µL of the supernatant into a new set of 1.5 mL Eppendorf tubes.
10. Ethanol precipitate the RNA. Add 30 µL of 3 M sodium acetate (0.1× volume), 120 µL
water. Mix well and add 750 µL of 100% ethanol (2.5× volume).
11. Mix well and place on ice for >30 min to precipitate RNA.
12. Spin at max (>16,000g) at 4°C or RT for ∼30 min.
13. Carefully remove the ethanol without dislodging the pellet.
14. Add ≥500 µL 70% ethanol, vortex, and centrifuge for 10 min to wash the pellet.
15. Carefully remove the ethanol and air dry the pellet for 2 min.
16. Resuspend pellet in 100 µL of nuclease-free H2O.
17. Optional: Examine fragmented RNA size distribution using TapeStation 2200 and RNA
Screen Tapes. Ensure the pattern has a strong peak spanning the region from 50 to 200 bp. For

96

poly A + samples, it is recommended to increase digestion strength to shift the peak toward even
smaller sizes.
18. Ethanol precipitate 5–6 µg fragmented RNA of each sample replicate.
Oxidation
To prepare the fragmented RNAs for subsequent elimination of the 3’-end bases to expose ribose
methylated bases that are potentially positioned one base upstream, these ends need to be
oxidized into dialdehydes using NaIO4.
19. Freshly prepare 200 mM NaIO4 solution by dissolving 42.78 mg of the NaIO4 powder per 1
mL oxidation buffer. Protect the solution from light. Important: This step should be performed
while precipitating the fragmented RNA and not earlier.
20. Dissolve RNA pellet in 30 µL oxidation buffer (make sure the pellet is well resuspended) and
add 10 µL of prepared NaIO4 solution. Mix well and incubate at room temperature protected
from light for 45 min (briefly vortex and spin the reaction tube every 15 min to ensure proper
resuspension of the pellet).
21. Adjust the volume to 90 µL with nuclease-free H2O. Add 10 µL H2O and 1 µL LPA.
22. Perform ethanol precipitation. Important: After adding 100% ethanol for precipitation and
centrifugation, white precipitates/film might be seen scattered on the Eppendorf tube wall due to
high salt content and a typical pellet might not be visible. This is normal. RNA can be recovered
if the orientation of the tube is kept consistent and a pipettor is used to vigorously flush and/or
gently scrap the precipitates/film off the wall after adding elimination buffer.
β-Elimination
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This step catalyzes the leaving of the 3’-end oxidized base to expose potentially 2’-O-methylated
bases at the 3’-end of the fragments.
23. Add 50 µL of β-elimination buffer to dissolve the pellet. Vigorously vortex, pipette up and
down, or invert the tube to further resuspend the oxidized RNA.
24. Spin the tubes briefly and transfer samples into PCR strip tubes. Tubes with individual caps
are highly recommended to prevent cross-contamination, especially in later steps where control
samples are handled alongside oxidation samples.
25. Using a thermal cycler, incubate at 45°C for 85 min.
26. Process samples through NucAway spin columns to remove unwanted small fragments and
salts from the samples (β-elimination alkaline conditions which can generate small undesirable
fragments).
27. Transfer samples into a new set of 1.5 mL Eppendorf tubes.
28. Ethanol precipitate and resuspend in 22 µL H2O as in the previous oxidation step. Adding
additional 0.5 µL LPA is highly recommended.
Phosphate removal and oxidation
To oxidize all 3’-ends that are not 2’-O-methylated, another NaIO4 treatment is needed.
However, after β-elimination, RNA fragment 3’-ends will contain a mixture of 3’-phosphates,
2’-phosphates, and/or 2’-3’-phosphates. It is vital to remove these phosphate groups to avoid
false positives in the final data representation. T4 PNK is used to remove all three types of
phosphates.
29. Transfer to PCR tubes.
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30. Remove 3’-, 2’-, and 2’–3’-cyclic phosphate using T4 PNK. (Important: The PNK buffer
used must not contain ATP.)

31. Incubate at 37°C for at least 4 h (longer incubation times may be OK and might be beneficial
as T4 PNK is an inefficient phosphatase).
32. Important: here is where control and oxidized samples are separated. Phenol–chloroform
extract the dephosphorylated RNA and aliquot 20% of the supernatant for each sample as
control, while the remaining 80% will go through final oxidation.
33. Ethanol precipitate controls and resuspend them with 16 µL H2O; at the same time, ethanol
precipitate oxidation samples into pellets (add 1 µL LPA for both). Store the controls in -80°C.
34. Freshly prepare 200 mM NaIO4 solution by dissolving 42.78 mg of the NaIO4 powder in 1
mL oxidation buffer. Protect the solution from light.
35. Dissolve the RNA pellet from oxidation samples thoroughly in 30 µL oxidation buffer.
36. Add 10 µL of prepared NaIO4 solution. Mix well and incubate at room temperature protected
from light for 45 min.
37. Transfer to a new 1.5 mL Eppendorf tube and ethanol precipitate RNA and resuspend in 16
µL H2O. If white precipitates remain in the solution, do not remove them.
38. Following these steps, the samples are properly oxidized.
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3’ DNA linker ligation
Ligation of 3’ linkers to unoxidized RNA 3’-ends will enable selective reverse transcription and
thus, enrichment of 2’-O-methylated RNA fragments. From this step on, control samples will be
subjected to the exact same procedures.
39. Thaw the control samples. Transfer 8 µL for each sample into PCR tubes.
40. Transfer 8 µL of each 16 µL oxidized sample into PCR tubes. Store the remaining 8 µL of
both control and oxidation for each sample at −80°C as backup.
41. Ligation of 3’ linker (prepare the reagents in a way that can be properly mixed, as the amount
of PEG 8000 added can make it difficult).

42. Incubate the reaction in thermal cycler at 16°C overnight for 18 h.
Anneal RT primer
Any 3’ linker not ligated in the previous step will still be freely available for ligation in the
samples. To ensure the 5’ RNA linker ligation attaches the RNA linkers to sample RNA
fragments but not to the free 3’ linkers during the next step, the RT primer is annealed first.
43. Add 1 µL of the 50 µM RT primer and 69 µL nuclease-free water to each sample.
44. Incubate in thermal cycler with the following program:
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90°C for 2 min
65°C for 10 min
4°C for 1 min
45. Phenol–chloroform extract and ethanol precipitate (add 1 µL of LPA) each sample and
resuspend in 11 µL H2O.
5’ RNA linker ligation
The double-stranded structures resulting from annealing the RT primers and free 3’ linkers will
prevent them from being ligated to the 5’ RNA linkers (Munafó and Robb 2010).
46. Thaw 50 µM RNA linker from −80°C and transfer (number of samples) *1.3 µL into a PCR
tube.
47. Denature RNA linker at 72°C for 2 min and return to ice.
48. Prepare the following ligation reaction.

49. Incubate at 25°C for 1 h, then terminate reaction at 65°C for 15 min.
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Reverse transcription
Because the RT primer has been annealed in the previous step, the RT reaction can proceed
without addition of primer. During this step, cDNA is synthesized. At the same time, randomhexamer sequences built into the RT primer are also incorporated into the cDNA library. These
will allow the removal of PCR duplicates later during data treatment.
50. Prepare RT reactions to generate a cDNA library using the following setup with SuperScript
III included reagents.

51. Incubate the reactions in thermal cycler following the kit's protocol.
52. Hydrolyze remaining RNAs by adding 4.4 µL of 1 N NaOH and incubate at 98°C for 20 min.
53. Add 22 µL 200 mM Tris-HCl PH = 7.0 to neutralize the PH.
54. Use Ampure XP beads at 0.8:1 ratio (add 53 µL Ampure XP solution). Incubate for 5 min to
let beads bind cDNA of sizes 250 bp and above.
55. Transfer supernatant to new tubes (discard beads) and add an additional 67 µL Ampure XP
solution to make the ratio 1:1.8. Finish Ampure XP purification.
56. Elute using EB buffer.
PCR amplification of cDNA library
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Illumina i5 and i7 PCR primer sequences have sequences complementary to the 5’ RNA linker
and RT primer sequences. This allows direct PCR amplification of the cDNA library. Periodate
oxidation enrichment in previous steps results in a cDNA library of very low complexity. Hence
it necessitates additional amplification cycles compared to construction of other types of
sequencing libraries (∼35 cycles versus ∼12 cycles). The strandedness of the final library is
second-strand similar to the library prepared using the Illumina ligation method.
57. Prepare NEB Q5 PCR reactions.

58. Incubate in the thermal cycler using the following program modified from the Q5 protocol. e
library prepared using the Illumina ligation method.

59. Add 25 µL of AmpureXP to achieve a 1:1 ratio to select for fragment of sizes ∼200 bp and
above, reducing the amount of non-insert fragments (Illumina i5 sequence: ∼70 bp, Illumina i7
sequence: ∼66, total non-insert product: ∼136 bp).
60. Purify libraries following the AmpureXP protocol. Resuspend each sample in 15 µL with
Illumina RSB (resuspension buffer).
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Library quantification
61. Use TapeStation and DNA Screen Tape to visualize library size distributions. It should have
a distribution around 200 bp. Even though stringent steps have been taken to avoid non-insert
PCR products, they may still be present and are expected.
62. Accurately measure library concentrations using the Qbit Fluorometer and dsDNA High
Sensitivity Reagent Kit (follow Qbit protocol).
63. Calculate library molarity using sizes and concentrations measured.
Sequencing
The NextSeq 500 (or MiSeq) 150 cycle Mid Output Kit is used in this experiment with 75 bp by
75 bp configuration.
64. Prepare and load the libraries for the NextSeq 500 sequencer following the established
protocol. Important: Make sure PhiX phage DNA comprises at least 30% of the total library if
the Riboxi-seq samples are the only samples being sequenced because of the nature of extremely
low diversity amplicon sequencing. The final loading concentration used in this experiment is
1.5 pM, which is slightly lower than the 1.8 pM from the protocol.
Data treatment
65. Remove read-through sequences. Because of the nature of the sequencing library preparation,
many fragments will have insert sizes significantly smaller than the 75 bp length sequenced by
the sequencer. The resulting read-through sequences will greatly impact alignment reliability.
Cutadapt (Martin 2011), a Python package, is used to first remove read-through sequences at the
3’-end for both read 1 and read 2. An in-house script has been used to compare randomer
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sequences and ∼5 bp RNA sequences to determine and collapse PCR duplicates on read 2.
Finally, we used cutadapt to remove the randomers and linker sequence from 5’-ends of read 2.
The resulting “.fastq” files can then be used for alignment.
66. TopHat2 is used to align the reads. The annotation file used consists of chrUn coordinates,
which contain two sets of 18S and 28S rRNAs, extracted from the hg19 index (Kim et al. 2013).
67. The “accepted_hits.bam” for each sample are sorted using SAMtools and converted to
“.BED” files using BEDtools (Heng et al. 2009; Quinlan and Hall 2010).
68. The third column of the “.BED” file represents the starting and ending positions (with respect
to 5’- and 3’-ends) of each read, while the sixth column indicates sense or anti-sense. We
counted the number of reads with 3’-end alignment for each position corresponding to 18S and
28S rRNA and generated a count table for each sample (only sense reads are taken, since the two
rRNAs we aligned to the reference sequence were transcribed from the sense strand).
69. The count data files were then imported into DESeq2 for differential analysis per base
position (Love et al. 2014).
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All raw and processed data produced from studies in this chapter II were deposited at the NCBI
Gene Expression Omnibus (GEO) with accession number: GSE96999.
All raw and processed data pertaining to T. brucei RibOxi-seq produced from experiments in
chapter III were deposited at the NCBI Gene Expression Omnibus (GEO) with accession
number: GSE102516 pending availability of corresponding publication.
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Chapter III
Application and Extension of RibOxi-seq
A. Abstract
The successful development of the RibOxi-seq provides us the foundation of an accurate,
robust and cost-effective way to studying 2’-OMe on rRNAs. Although from an evolutionary
perspective, T. brucei is very distant from human within the Eukarya domain, the conservation of
2’-OMe machineries is an interesting observation. Although there have been a large number of
snoRNAs identified, as well as bioinformatically predicted corresponding 2’-OMe sites on T.
brucei’s rRNAs, the number of experimentally validated sites remains much smaller. Besides the
field of epitranscriptomics gaining attraction, more evidence suggests an increasing importance
of 2’-OMe in different life stages of T. brucei. Therefore, we sought to profile 2’-OMe
landscapes of different stages of the organism to help better understanding the biology of its
lifecycle and to further highlight the power and potential of RibOxi-seq. In addition, we would
like to be able to answer the questions asked in Chapter I such as: are there internal 2’-OMe sites
within mRNAs and can we identify targets for orphan snoRNAs? We performed pilot
experiment on mouse mRNA, as well as human ESC WT mRNA and SNORD116 KO mRNA.
In both human and mouse, RibOxi-seq suggests a strong likelihood of detecting 2’-OMe sites,
pending validation with an independent method, and shows interesting patterning of the
modification distribution. With some technical difficulties still present, we are still actively
exploring ways to analyze and compare WT and KO data.
B. Background
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Trypanosomes. T. brucei is a protistan parasite causing deadly disease in sub-Saharan
Africa. During its life cycle the parasite shuttles between its tsetse fly vector and human host
where it lives freely in the bloodstream. For a rather small genome (35Mb haploid vs. human:
3200Mb diploid), trypanosomes encode a large repertoire of snoRNAs. (Schultz et al. 2006,
Uliel et al. 2004). Although there have been continuous efforts made to map sites of 2’-OMe in
trypanosomes, only a few laboratories around the world have pursued RNA modifications study
in parasitic organisms. Over the years, evidence for individual sites slowly accumulated mainly
contributed by targeted primer extension studies; however, a lack of curated reports or databases
documenting known sites that are experimentally validated renders 2’-OMe patterns in T. brucei
and related organisms elusive. Currently, more than 20 snoRNA clusters encoding more than 50
Box C/D snoRNAs have been identified in transcriptomic studies, suggesting a capability of
modifying more than 130 sites in rRNA alone. A significant portion of these 130 sites, unlike
human counterparts, are bioinformatically predicted rather than exhaustively validated (Liang et
al. 2005, Uliel et al. 2004, Barth et al. 2008).
Interestingly, a recent semi-large-scale primer extension study revealed the possibility of
differential 2’-OMe patterns between the mammalian-infective bloodstream and insect-stage
procyclic forms (BF and PF) of T. brucei (reviewed in Ponte-Sucre 2016). The detection of
methylation level changes in certain sites, rather than a change in overall methylation levels,
provided evidence for possible functional involvement of 2’-OMe in the life cycle of the parasite
(Barth et al. 2008). With the opportunity to form a close collaboration with Dr. Arthur Günzl’s
lab within our department as well as the Günzl lab’s collaborators who are experts in
Trypanosome 2’-OMe, we decided that it would be appropriate and feasible to determine and
compare rRNA 2’-OMe profiles between T. brucei life cycle stages.
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Mammalian sites of 2’-O methylation. In Chapter II, I discussed that if we want to adapt
RibOxi-seq for detection of low abundance transcripts, such as mRNAs, additional rounds of βelimination would likely be necessary. However, each round involves several hours of work. We
alternatively speculated that if we simply increased digestion time length, the odds of sites on
mRNAs being exposed should increase. Even though there will be significant potential loss on
number of sites that could have been detected with extra β-elimination, this pilot study only
serves as proof-of-principle that there are mRNA internal 2’-OMe and that they can be detected
by RibOxi-seq.
Introns of ribosomal protein L13a (Rpl13a) codes for a group of snoRNAs including U32a,
U33, U34 and U35a, whose rRNA targets have been known. Interestingly, snoRNAs from the
Rpl13a locus are critical regulators of reactive oxygen species and oxidative stress (Michel et al.
2011, Lee et al. 2016). In an animal model of diabetes from drug-induced beta cell injury,
genetic loss of the Rpl13a snoRNAs (-/-) reduces oxidative stress, confers partial resistance to
development of diabetes, and also leads to recovery from injury beta-cell injury with
normalization of blood glucose over time. Although box C/D snoRNAs were not previously
known to target mRNA for modification, the Holley Lab has shown preliminary data that these
snoRNAs might target mRNA for 2’-OMe modification as a novel mechanism of action (Holley
et al. 2015, Holley lab unpublished data). Therefore, we formed a collaboration in the hope of
finding direct evidence for the methylation on mRNA and gaining insights on clinical relevance
of 2’-OMe.
SNORD116 is a box C/D snoRNA cluster residing within chromosome 15 q11-q13 region.
There are 30 similar snoRNAs encoded by the cluster (Cavaillé et al. 2000). Prader-Willi
syndrome (PWS) is a genetic disorder resulted from certain deletions within the region. PWS
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disrupts normal functions of hypothalamus neurons, including abnormal hormone levels
(reviewed in Cassidy et al. 2012). However, the underlying molecular basis of the disease is not
well understood. The locus contains several genes, although interestingly, SNORD116 deletion
always accompanies PWS patients (Bieth et al. 2015). Thus, the 2’-OMe aspect of the disease
have not been explored as the SNORD116 cluster snoRNAs are orphan snoRNAs that lack
known targets. Thus, we would like to investigate whether the SNORD116 snoRNAs have 2’-Omethylation targets and whether the methylation process is involved in the pathology by
investigating human 2’-OMe patterns transcriptome-wide.
C. Methods and Materials
1. RNA extraction and PolyA RNA isolation
Total RNA from axenic T. brucei cultures (both BF and PF were cultured in Günzl lab) were
prepared using PureLink® RNA Mini Kit following manufacturer’s protocol (with on-column
DNAse treatment). Total RNAs from U32KO/WT mice livers were supplied by Holley lab from
Duke University. SNORD116 KO/WT H9 human embryonic cell lines were provided by
Michael Chung from the Chamberlain lab, and RNA extractions were performed using
PureLink® RNA Mini Kit. mRNAs were enriched for mouse and H9 samples using
PolyATtract® mRNA Isolation Systems from Promega.
2. RibOxi-seq
Standard RibOxi-seq was performed on both T. brucei PF vs. BF total RNA samples, and H9
SNORD116 WT vs. KO total RNA samples with 2 biological replicates each. RibOxiseq-seq
protocol was slightly modified in order to improve possibilities for mRNA-site detection. The
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modified protocol was performed on the following sample sets with 2 biological replicates each:
mouse U32 WT vs. KO mRNAs; and human H9 SNORD116 WT vs. KO mRNAs.
D. Results
1. Profiling of T. brucei 2’-OMe rRNA landscape supports life stage-specific and sitespecific differential methylation
As mentioned earlier, there has been no curation of experimentally validated T. brucei 2’OMe sites for rRNAs to date. However, snoRNA repertoire has been extensively examined,
which also generated a number of 2’-OMe predictions (Michaeli et al. 2012). Currently, Dr.
Shulamit Michaeli’s lab (one of our collaborators), is consolidating evidence of Trypanosome
rRNA 2’-OMe from various sources including bioinformatic predictions, targeted primer
extension experiments, structural studies, 2’-OMe-seq and known snoRNAs. The goal is to cross
check between different 2’-OMe detection methods and corresponding snoRNAs. Eventually,
each position will be evaluated based on cumulative evidence and a cutoff will be set for
determination of the methylation status. Since RibOxi-seq performed very well on human rRNA
site-detection, we were optimistic about its potential contribution to this collaborative effort.
Overall 2’-OMe patterns generated through RibOxi-seq between the two life stages are
remarkably similar when visualized on the IGV genome browser (Figure 17A). Interestingly,
after filtering the DESeq2 statistical analysis output list with adjusted p-value<0.000001 and
log2 fold change>6, we observed highly comparable high-confidence sites between the two life
stages with minor differential methylation (Figure 17B). When comparing to data in the lists
currently being compiled as well as the data from MIchaeli et al. (2012), our results
experimentally confirmed many of the predicted sites, while validated known sites in a single
experiment (Table 8). One interesting observation we made comparing to the compiled data was
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that many sites, which are both validated and detected by RibOxi-seq, showed no evidence in
existing bioinformatic predictions, underscoring the limitations of algorithms of current tools.
When compared to 2’-OMe-seq data, there are a number of agreements and disagreements.
However, we argue that our method should represent a rather accurate picture of the 2’-OMe
sites because the principle of the chemistry of our approach. Regardless, there are a few
candidates that received strong scoring for being potential sites and which are differentially
methylated between life stage differences and worth following up using independent approaches
(Table 5). How relevant and important differential methylation is on these sites is for T. brucei
biology will require further investigation.
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Figure 17. RibOxi-seq on T. brucei BF and PF total RNA samples.
(A) Visualization of read alignment of RibOxi-seq data for both BF and PF. Region selected is
18S rRNA region. Genome build is Tb427. Each track represents 2’-OMe patterns of the two
replicates of the BF and PF respectively.
(B) After statistical analysis, example of sites that have significant differential methylation
observations. Purple peaks represent positions that have log2 fold change of greater than or
equal to 6, while adjusted p value is less than 10e-7; Blue peaks represent positions that have
log2 fold change of less than 6, while adjusted p value is less than 10e-7; And Blue peaks
represent positions that have log2 fold change of greater than 6, while adjusted p value is
greater than 10e-7. In general, only the purple positions are considered once cutoffs are set.
Here we selected a few sites that are differentially detected between the two life cycle forms.
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Table 5. List of promising differentially methylated sites in T. brucei to follow up.
rRNA

Base
position

Modification

Box C/D
snoRNA

Prediction

Primer
extension

2'-OMe-seq

LSU5

1742

Um

TB7Cs2C1

Yes

?

Yes

LSU5

916

Um

TB11Cs4C2

Yes

Y

Yes

LSU3

601

Cm

TB10Cs1C1

Yes

Y

Yes

LSU3

1264

Cm

TB6Cs1C1

Yes

?

Yes

RibOxiseq
Yes, PF
Only
Yes, PF
Only
Yes, PF
Only
Yes, PF
Only

These sites were confirmed in bioinformatic prediction based on snoRNA sequence, validated
using primer extension experiment, detected using 2’-OMe-seq, and detected in RibOxi-seq.
Specifically, RibOxi-seq only detected them in PF samples.
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2. RibOxi-seq can detect mRNA 2’-OMe sites for genes abundantly expressed in
corresponding cell lines or tissues.
Our original speculation was multiple extra β-elimination steps would be required. However,
we were concerned that if starting material is limited, each additional step, which needs to be
carried out under alkaline conditions and at elevated temperature, could result in accumulation of
RNA breakages and thus extensive loss of material. We expect occurrences of 2’-OMe sites on
mRNAs are much less frequent events than on the abundant and highly structured rRNA, which
could lead to very little material for reverse transcription after oxidation of RibOxi-seq
procedures. With a low RNA abundance RT reaction, it has been known that strong background
noise and artefacts can occur (Levesque-Sergerie et al. 2007). Most specifically mis-priming,
which is resulted from primer partial hybridization with non-specific targets, can generate ‘fake’
peaks. In this case, all sequences upstream of detected peaks would appear to contain a motif
having high to perfect resemblance to part of the RT primer (Gillen et al. 2016). Such patterns
were evidenced in a methodology, using same principles, that was published the same time as
RibOxi-seq. Significant mis-priming events consisted of almost 40% of their mRNA sites
obtained from initial RNA fragments that underwent 13 additional rounds of elimination (Dai et
al. 2017). Also, total RNA, rather than poly(A)+ RNA, was used in the protocol, leading to the
possibility of further complications. Interestingly, the corrigendum published later in an attempt
to address the mis-priming artefact generated data-sets that have no overlap with the original
published data-sets, even the 60% of sites that reportedly showed little similarity to the
sequencing primer (https://www.nature.com/articles/nmeth0318-226c).
To circumvent this potential pitfall, we argue that if we purify poly(A)+ RNAs and perform
very extensive digestion to increase 2’-OMe exposure after a single step of beta elimination, we
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may be able to detect at least some sites in mRNAs. Thus, from purified mouse liver poly(A)+
RNAs and human H9 poly(A)+ RNAs, we modified the digestion temperature to generate RNA
fragment pools with an average length of 36bp, while the remaining steps of the RibOxi-seq
were unchanged (Figure 18). Because rRNAs are highly abundant (making up more than 95% of
total RNAs), even with poly(A)+ RNA purification, it is inevitable that we still detect rRNA
sites. Conveniently, this allows us to use the rRNA region as an internal control to ensure the
RibOxi-seq chemistry worked.
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Figure 18. New Benzonase digestion optimization for RibOxi-seq.
Digestion incubation temperature was elevated to room temperature, and incubation time was 20
minutes. The resulting digestion products are now with sizes averaging 35-40bp long.
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Our results show that experiments on both mouse and human RNAs are largely consistent
with known sites in the rRNA region (Figure 19). However, when we examine the data for the
rest of the transcriptome, we discovered several issues. First, we witnessed variable mis-priming
events, where observed sites have upstream ‘motifs’ that have 3-8bp matching sequence with the
RT primer sequence (Figure 20). Our bioinformatic capabilities did not allow us to filter these
sites out quickly as these are of variable length and some contain regions of base pair
mismatching. As a consequence, we manually scanned through the genome on the UCSC
genome browser and recorded non-mis-priming sites. Another type of seeming artifact is the
occurrence of peak doublets with certain lengths of spacing. When examining UCSC tracks for
H9 data between a total RNA experiment and a poly(A)+ RNA experiment, we discovered that
the poly(A)+ RNA experiment detected almost all known sites in the rRNA region. However,
unlike total RNA data, the poly(A)+ RNA data set also displayed additional peak doublets. When
we manually filtered out these peaks, total RNA and poly(A)+ RNA data sets became consistent
with each other.
Such phenomena suggested that any site that is close to or part of similar doublet peaks are
best ignored. In the end, we observed several sites that appear to be real sites. Our final list of
sites in H9 cell corresponds to abundantly expressed genes such as desterin, NOMO family
genes (NODAL modulators) etc. (Table 9); while mouse datasets generated from liver RNA
experiment are still under examination, we found genes such as transferrin, a liver specific gene,
is one of the promising sites after filtering (Figure 21).
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Figure 19. RibOxi-seq on poly(A)+ enriched mouse liver RNAs and human H9 cell line
RNAs.
Top panel is the visual representation of mouse liver 2’-OMe alignment against mm10 genome
after performing RibOxi-seq. results between biological replicates are highly consistent with
each other. By comparing our site detection with snOPY database reveals that our method can
confidently detect mouse 2’-OMe sites (http://snoopy.med.miyazaki-u.ac.jp/).
Bottom panel. RibOxi-seq alignment visualization for H9 RNA 2’-OMe 18S rRNA sites.
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Figure 20. Common artefact occurred during RibOxiseq for transcriptomic 2’-OMe
mapping.
Post NaIO4 oxidation only a fraction of terminally methylated RNA fragments remains intact,
who are then being ligated to a 3’- linker. The ligated linker act as an anchor point for
subsequent reverse-transcription. Due to extremely low abundance of RNA fragment and
relatively high concentration of primer oligoes, primer can anneal non-specifically and generate
RT products. In the figure, the relative position of such artefact is shown.
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Figure 21. Examples of genes with likely mRNA 2’-OMe sites.
Oxidized samples have promising peaks in NOMO1 and desterin locus. These are not found to
be associated with any known chemistry artefact.
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Oxidized 1

Control 2

Oxidized 2

Control 1

Oxidized 1

Control 2

Oxidized 2
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E. Discussion
In this chapter, we have demonstrated the applicability of the RibOxi-seq method to rRNAs
in non-PA1 cell lines and even cells from different organisms. Our results corroborated the
evidence that methylation status change of specific Trypanosome rRNA 2’-OMe sites between
two life stages might be regulated individually. However, how and why such differential patterns
occur will require further investigation. One possible way for organisms like mammals is that
snoRNAs spliced from introns of host genes can be regulated depending on the host gene
expression levels, thus achieving cell type-specific snoRNA expression levels and ultimately cell
type -specific 2’-OMe levels. However, there is no evidence of snoRNAs processed from introns
of T. brucei genes. Then how are snoRNAs of T. brucei regulated? Since T. brucei snoRNAs are
transcribed and processed into polycistronic transcripts before maturation, it is likely pertaining
to post-transcriptional regulation (reviewed in Siegel et al. 2011).
In trying to adapt RibOxi-seq to poly(A)+ RNAs, we have learned that the protocol likely
needs to be further tweaked and optimized. It was encouraging to show that we were able to
detect rRNA sites even with poly(A)+ RNA isolation performed, indicating RibOxi-seq is more
flexible than originally anticipated in terms of the amount of required starting materials. Based
on such observations, we thus updated the current working protocol. However, mapping sites on
mRNAs proved to be more complicated than expected. Although rRNA regions worked well as
internal controls, potential artifacts and low read counts in the rest of the transcriptomic regions
in non-oxidized samples makes it difficult control for non-specific sites. Our original goal of
comparing 2’-OMe sites transcriptome-wide on the WT and SNORD116 snoRNA KO samples
we have are therefore intractable at this moment. We will need to further test and make
adaptations to the method in order to achieve such capability.
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Chapter IV
Conclusions and Future Directions
In summary, we have described in this thesis of successful development of a novel highthroughput method for detection of 2’-OMe in rRNAs - RibOxi-seq. In addition, we have
demonstrated wide applicability of the RibOxi-seq through experiments on multiple human cell
lines, mouse liver cells, and two T.brucei cell types. Through performing RibOxi-seq on human
cell lines, we showed that rRNA transcripts within the same cell type are not modified identically
(Refer to explanation in chapter 2 and Table 3). We also showed that a decrease in snoRNA
levels might not contribute to significant changes in methylation levels. By applying RibOxi-seq
to T.brucei RNAs and cross confirmation with collaborations, we corroborated the evidence that
methylation patterns could be life cycle or developmental stage specific. In trying to adapt the
methodology for transcriptome-wide detection, we realized that how the abundance of the
transcripts remains a hurdle even when purified poly(A)+ RNAs were used. However, after
efforts to filter out possible artifacts, we produced a list of sites that could prove to be real sites,
suggesting that we could still achieve transcriptome-wide detection after further optimization of
each step of the protocol. Overall, the patterns that our candidate sites correspond to abundantly
expressed genes in any particular cell type indicates the method might be restricted to transcripts
that are highly expressed. To follow up on the results described in this thesis, two immediate
aims will be proposed for future investigation of functions of the 2’-O-methylation.
1. rRNA 2’-OMe landscape profiling of primary cells involved in diseases such as cancers.
Are there associations between rRNA methylation abnormalities and diseases?
rRNAs are most heavily 2’-O-methylated RNA transcripts. Because methylation patterns were
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shown to vary between different cell types, we speculate such process forms a layer of
regulation, and thus mis-regulation of such process can contribute to pathogenesis (Figure 17B,
Table 6, Krogh et al. 2016). To test this possibility, we would choose a cancer type, such as
melanoma. The rationale is that cancer cells are highly proliferative, thus requiring high
ribosomal capacity, where 2’-OMe mis-regulation is likely to occur. We would like to extract
total RNA from primary melanoma cells and matching wild type cells and perform RibOxi-seq.
To achieve statistical validity, we reason that we should obtain maximum number of samples as
long as cost and sample source allow. The rRNA 2’-OMe sites will be analyzed and compiled for
examination of whether there are common depletions or enrichments of modifications at certain
sites.
2. Strategies to properly adapt RibOxiseq to transcriptome-wide application.
Do currently identified mRNA 2’-OMe sites have merit? Validation of 2’-OMe sites
on low abundance RNAs have been historically difficult as discussed in the previous chapter.
Primer extension is in general a very sensitive method even for low abundance RNAs, however,
we do not know the characteristics of primer extension under low dNTP concentration is
(Raymond 2005). Although, PCR amplification coupled with primer extension has been used in
several occasions, it is undesirable as it can introduce further noise into the visualization (Holley
et al. 2015). Conveniently, the seemingly high efficiency of the snoRNP machinery suggests that
it can have much higher methylation capacity than the normal biological requirement for
ribosome biogenesis (Figure 22, Newton et al. 2003). Thus, we reason that if we overexpress
genes that are on our list such as desterin or NOMO1, and perform primer extension with gene
specific primers, we should see corresponding bands if those sites are indeed real. It is also
important to determine if these potential methylation sites are guided by any expressed
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snoRNAs. As small RNA sequencing technology matured over the past years, it is now possible
to accurately profile box C/D snoRNA expression levels through CLIP-seq with antibody to
NOP58 protein (Gumienny et al. 2017). Subsequently, the surrounding sequences of the 2’-OMe
sites can be bioinformatically analyzed against CLIP-seq snoRNA, from the same cellular
source, results to determine the guide RNAs.
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Figure 22. Alternative strategy for validating low abundance RNA 2’-OMe.
Overexpression plasmids are transcribed by RNA Pol II, and the overexpressed transcripts
undergo same paths as endogenous mRNAs. Thus, if endogenous transcripts are modified with
2’-OMe, the overexpressed copies, at least a significant amount of them, will have 2’-OMe. This
can help with detection signal to noise ratio.
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Protocol optimizations for the Illumina platform. So far, reaction composition for
each enzymatic step of the RibOxiseq-protocol after oxidation follows manufacturer’s
instructions with RNA quantity estimates made from the original sample. Thus, we will perform
RibOxi-seq library preparation steps until first ligation. We will then use the entire sample to
quantify RNA fragment average size and molarity to determine optimal reaction condition. We
will extend such strategy to cover all remaining steps. By using such strategy, we should be able
to minimize significant amounts of potential artifacts of RibOxi-seq.
Modify RibOxi-seq to work with Oxford nanopore direct RNA sequencing. Recently,
the Minion sequencing platform became widely available. One of the breakthroughs made by
this platform is the capability of direct RNA sequencing (Garalde et al. 2018). As a consequence,
the library preparation step consists of just two ligations, removing the necessity of conversion to
cDNA and PCR amplification. We reason that by adapting RibOxi-seq to the Oxford nanopore
platform, we would greatly reduce bias and experimental artifact. In addition, the method can
also become quantitative as the only major variable is ligation efficiency. We will design custom
oligos so that they can only be ligated to 2’-O methylated ends but not dialdehydes. The oligos
can be easily designed to be compatible with the new sequencing platform. In principle, there
appear to be no technical barriers for this adaptation, and we will investigate its validity (Figure
23).

134

Figure 23. Strategy to adapt RibOxi-seq to Oxford Nanopore direct RNA sequencing.
The direct RNA sequencing protocol requires two simple ligation steps for conversion of RNA
of interest into RNA library. The second ligation step is universal, while only the first ligation is
target specific. The RNA adapter denoted Oligo A/B duplex can be modified to accommodate
random annealing and ligation instead of AAAAAAAAAA to UUUUUUUUUU annealing.
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Table 6. List of reagents and equipment used in RibOxi-seq
Reagents
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Seal-Rite 2.0 mL microcentrifuge tube, natural (USA Scientific, 1620-2720)
PA-1 [PA1] cell line (ATCC, CRL-1572)
PureLink RNA Mini Kit (Thermo Fisher Scientific, 12183025)
PureLink DNase Set (Thermo Fisher Scientific, 12185010)
TURBO DNA-free Kit (Thermo Fisher Scientific, AM1907)
Ultra-pure Benzonase (Sigma, E826305KU)
10× Benzonase buffer (store at 4°C)
3 M sodium acetate pH = 5.2
Ethanol 100%
Ethanol 70%
UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) (Thermo Fisher Scientific,
15593031)
Acid-Phenol:Chloroform, pH 4.5 (with IAA, 125:24:1) (Thermo Fisher Scientific,
AM9720)
NucAway Spin Columns (Thermo Fisher Scientific, AM10070)
RNA Analysis ScreenTape (Agilent, 5067-5576)
RNA Analysis ScreenTape reagents (Agilent, 5067-5577)
High sensitivity D1000 DNA ScreenTape (Agilent, 5067-5584)
High sensitivity D1000 DNA ScreenTape reagents (Agilent, 5067-5585)
Linear polyacrylamide 10 µg/µL (Mullins Molecular Retrovirology Lab Short protocol)
Sodium meta-periodate (Sigma-Aldrich, 7790-28-5)
Sodium periodate oxidation buffer: 4.375 mM sodium borate, 50 mM boric acid, pH =
8.6
0.2 mL PCR 8-tube FLEX-FREE strip, attached clear flat caps, natural (USA Scientific,
1402-4700)
β-elimination buffer: 33.75 mM sodium borate, 50 mM boric acid, pH = 9.5
T4 Polynucleotide Kinase (NEB, M0201L)
SUPERase• In RNase Inhibitor 20 U/µL (Thermo Fisher Scientific, AM2696)
RNaseOUT Recombinant Ribonuclease Inhibitor (Thermo Fisher Scientific, 10777019)
T4 RNA Ligase 2, truncated KQ (NEB, M0373S)
T4 RNA Ligase 1 (NEB, M0204S)
DMSO 100%
SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific, 18080051)
Sodium hydroxide 1 N
EB buffer: 10 mM Tris-Cl, pH 8.5
Q5 High-Fidelity 2× Master Mix (NEB, M0492S)
Agencourt AMPure XP, 450 mL (Beckman Coulter Life Sciences, A63882)
Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, Q32854)
NextSeq 500/550 Mid Output v2 Kit (150 cycles) (Illumina, FC-404-2001)
Shrimp alkaline phosphatase (rSAP, NEB, M0371S)
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Equipment
Table top centrifuge
Programmable thermal cycler
Heat blocks/water baths
NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, ND-2000)
2200 TapeStation (Agilent Technologies, G2964AA)
Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Q32866)
NextSeq 550 System (Illumina)
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Table 7. List of primers and other oligos used.
RibOxi-seq Primers and linkers:
3′ Preadenylated DNA linker (NEB Universal miRNA Cloning Linker, S1315S, dissolve into
50 µM)
•

5′-/rApp/CTGTAGGCACCATCAAT/NH2/-3′

5′ RNA linker (50 µM stock)
•

5′-/Biosg/rArCrArCrGrArCrGrCrUrCrUrUrCrCrGrArUrCrU-3

Reverse transcription primer (50 µM stock)
•

5′GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTRANATTGATGGTGCCTACA
G-3′

(Important: The “RAN” represents a customizable random hexamer sequence that can be
used to remove PCR duplicates later in the data analysis. Random hexamer sequences are
used in the experiments, but longer is recommended for higher sequencing depth.)
Illumina compatible barcoded PCR primers
•
•

i5: 5′-aatgatacggcgaccaccgagatctacacBARCODEacactctttccctacacgacgctcttccgatct-3′
i7: 5′-caagcagaagacggcatacgagatBARCODEgtgactggagttcagacgtgtgctcttccgatct-3′

(Barcodes are customizable. The protocol is established using paired-end sequencing with
dual barcodes. Important: When demultiplexing, the i7 barcode sequence needs to be
specified as reverse complement to what is in BARCODE).
It is possible to design longer linker sequences, matching RT primer and PCR primers to
increase amplification specificity and efficiency.
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Primers for cDNA validation:
Forward:
28S-1 GCTCTCCCACCCCTCCTC
28S-2 CGCAGGTGCAGATCTTGGT
Reverse:
RibOxi-seq RT Primer w/o hexamer:
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT ATTGATGGTGCCTACAG

RT primer sequences for radioactive dNTP concentration dependent primer extension:
LSU C1880 (positive control):

5’-ATGGCCACCGTCCTGCT-3’

SSU U1668 (not detected):

5’-ATCCGAGGGCCTCACTA-3’

LSU A3717 (Novel):

5’-GGCATTTGGCTACCTTA-3’

Anti-sense oligo (ASO) for U63 snoRNA KD:
U63_1:
mA*mG*mU*mU*mU*T*C*C*A*C*A*C*G*T*T*mC*mU*mU*mU*mC
U63_2:
mC*mU*mC*mA*mG*T*C*A*T*T*A*G*T*T*T*mU*mC*mC*mA*mC
Non-specific Control:
Proprietary scrambled LNA oligo from Exiqon

Primers for U63KD qPCR:
Forward:
ATCATTCTGAAAGAACGTGTGG
Reverse:
Universal reverse primer from miScript II RT PCR kit
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Table 8. List of 2'-OMe sites detected in T. brucei using RibOxiseq
5.8S
Modification
Um
Am
Am
Gm
Am

Position
7
41
43
75
163

Predictions
TB10Cs1C3

18S
Modification
Cm
Um
Cm
Am
Um
Cm
Um
Am
Um
Cm
Cm
Um
Um
Am
Am
Am
Cm
Um
Um
Um
Um
Um
Um
Gm
Um
Um
Gm
Gm
Gm
Gm
Gm

Position
16
36
46
56
57
66
123
125
386
507
668
680
714
721
738
818
819
977
996
999
1002
1038
1425
1432
1433
1447
1517
1531
1532
1603
1628

Predictions
TB10Cs2C1
TB10Cs2C1
TB8Cs3C3
TB8Cs2C1

TB10Cs7C3a/b
TB8Cs3C3
TB9Cs4C2

TB8Cs2C1
TB8Cs1C2

TB10Cs3C3
TB9Cs2C6
TB6Cs2C1

TB11Cs3C2
TB3Cs1C1
TB3Cs1C1
TB8Cs3C2

Primer extension
N/A
N/A
N/A
N/A
N/A

RibOxi-seq PF
No
Yes
Yes
Yes
Yes

RibOxi-seq BF
No
Yes
Yes
Yes
Yes

Primer extension
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Yes
N/A
Yes
N/A
N/A
N/A
N/A
N/A
Yes
Yes
Yes
Yes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Yes
N/A

RibOxi-seq PF
No
No
No
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes

RibOxi-seq BF
No
No
No
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
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Um
Um
Um
Gm
Gm
Gm
Am
Gm
Cm
Um
Um
Am
Cm
Gm
Um
Gm
Cm
Am
Am
Um
Cm
Am
Cm
Um
Um
Cm
Um
Gm
Cm
Gm

1630
1652
1674
1675
1676
1678
1680
1700
1758
1843
1844
1871
1887
1895
1899
1931
1932
2016
2050
2054
2089
2096
2104
2122
2123
2134
2154
2156
2216
2227

TB10Cs2"C3
TB10Cs1C3
TB10Cs3C2

28S Alpha
Modification
Am
Um
Am
Am
Am
Am
Cm
Am
Gm
Cm

Position
254
306
713
743
744
746
760
762
880
887

Predictions
TB10Cs3C2

TB9Cs3C1

TB10Cs2"C1

TB7Cs1C1

TB9Cs2C4
TB11Cs2C1
TB10Cs4C4
TB10Cs4C2

TB8Cs2C0
TB9Cs3C2

TB10Cs4C3
TB10Cs4C3

TB8Cs1C1

TB9Cs2C2
TB10Cs2C2
TB9Cs2C2

N/A
Yes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Yes
N/A
Yes
N/A
Yes
N/A
N/A
Yes
Yes
N/A
Yes
Yes
Yes
N/A
N/A
Yes
N/A
N/A
Yes
N/A

No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes

No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes

Primer extension
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Yes
N/A

RibOxi-seq PF
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No

RibOxi-seq BF
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
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Cm
Um
Gm
Um
Gm
Am
Cm
Gm
Am
Gm
Am
Gm
Um
Cm
Um
Am
Gm
Gm
Um
Um
Am
Am
Um
Um
Um
Gm
Um
Gm
Am
Am
Um
Um
Gm
Gm
Cm
Am
Gm
Gm
Gm
Um

912
914
915
916
925
927
970
976
986
992
996
998
999
1006
1019
1024
1027
1028
1145
1166
1179
1180
1181
1218
1229
1267
1330
1369
1379
1391
1406
1448
1572
1605
1608
1620
1621
1634
1709
1742

TB8Cs1C3
TB8Cs1C1
TB7Cs2C1

N/A
N/A
Yes
Yes
N/A
Yes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Yes
N/A
N/A
N/A
Yes
Yes
N/A
N/A
N/A
Yes
Yes
Yes
Yes
N/A
N/A
N/A
Yes
Yes
N/A
Yes
Yes
N/A

Yes
No
No
Yes
No
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
No
No
No
Yes
No
Yes
Yes
Yes
Yes
No
Yes
Yes

Yes
No
No
No
No
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
No
No
No
Yes
Yes
No
No
No
Yes
No
Yes
No

Prediction

Primer extension

RibOxi-seq PF

RibOxi-seq BF

TB9Cs2C3
TB11Cs4C2
TB9Cs2C3
TB11Cs4C2

TB10Cs4C5
TB9Cs5C2

TB9Cs5C1
TB11Cs1C3
TB9Cs2C5
TB10Cs3C4

TB9Cs5C1
TB10Cs3C4

TB9Cs4C1
TB10Cs5C1

TB8Cs2C2
TB10Cs2"C3
TB8Cs3C1
TB8Cs3C1

28S Beta
Modification

Position
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Gm
Um
Am
Cm
Um
Am
Am
Um
Am
Am
Am
Am
Um
Um
Gm
Um
Am
Am
Um
Cm
Am
Am
Am
Am
Gm
Um
Gm
Um
Um
Um
Um
Um
Cm
Um
Gm
Gm
Gm
Um
Cm
Am
Gm
Gm
Cm

71
73
95
377
391
395
400
418
439
520
544
545
546
550
552
578
588
590
596
601
609
621
622
646
659
672
673
685
719
728
729
931
969
1011
1019
1062
1094
1098
1175
1201
1245
1247
1264

TB9Cs1C1
TB3Cs3C1
TB9Cs4C3

TB6Cs1C2
TB11Cs2C1
TB10Cs7C2
TB6Cs1C3

TB10Cs1C4
TB11Cs3C1
TB8Cs1C3

TB10Cs1C1
TB10Cs1C1
TB10Cs2'C1
TB11Cs4'C1
TB9Cs2C7
TB11Cs4C3
TB9Cs2C7
TB10Cs3C5
TB10Cs3C5

TB6Cs1C2
TB11Cs2C1
TB5Cs1C1
TB5Cs1C1
TB10Cs2"C2
TB3Cs1C-1
TB11Cs1C2
TB6Cs1C1

N/A
N/A
N/A
Yes
Yes
N/A
Yes
Yes
N/A
N/A
N/A
Yes
N/A
N/A
Yes
Yes
N/A
N/A
N/A
Yes
Yes
N/A
Yes
N/A
N/A
Yes
N/A
Yes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Yes
N/A
N/A
N/A
N/A
Yes
Yes
N/A
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No
Yes
Yes
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
No
Yes
Yes
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
Yes
Yes
Yes
No
Yes
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
No
Yes
No
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No

Gm
1269
TB11Cs1C2
Yes
Yes
Yes
Gm
1293
Yes
No
No
Gm
1295
Yes
No
No
Cm
1333
Yes
No
No
Um
1336
Yes
No
No
Gm
1349
Yes
No
Yes
Um
1375
TB10Cs3C1
Yes
Yes
No
Gm
1376
N/A
Yes
Yes
Am
1388
TB11Cs4C1
Yes
Yes
Yes
Am
1400
TB11Cs4C1
Yes
Yes
Yes
Am
1412
N/A
Yes
No
Cm
1413
TB9Cs2C1
N/A
Yes
Yes
Um
1429
N/A
Yes
Yes
Um
1434
N/A
Yes
Yes
Um
1435
TB9Cs3C3
N/A
Yes
Yes
Sites detection is summarized from 5.8S, 18S, 28S alpha and 28S beta rRNAs. Detected sites are
compared with bioinformatic predictions and previous experimental data from Michaeli lab and
Michaeli et al. (2012).
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Table 9.
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